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ABSTRACT 
Syed Muaz Khalil: Characterization of alphavirus replicon based vaccines and adjuvants in a 
neonatal murine model 
(Under the direction of Laura J. White) 
 
Infectious diseases are the leading cause of childhood morbidity and mortality 
worldwide. Not only is there a lack of vaccines for many deadly diseases, early life 
immunization with the available vaccines is frequently ineffective and requires multiple doses to 
induce protective immune response. Additionally, the neonatal immune responses to infection 
and vaccination are biased towards TH2 at the cost of pro-inflammatory TH1 responses needed to 
combat intracellular pathogens.  However, upon appropriate stimulation, the neonatal immune 
system can induce adult-like TH1 responses. We hypothesized that non-propagating Venezuelan 
equine encephalitis virus replicon (VEE)-based vaccine platforms (VRP) are good candidates for 
safe early life immunization, based on their ability to (1) target dendritic cells (DC) in the 
draining lymph node and (2) induction of robust innate immune response through intracellular 
amplification of replicon RNA. 
In the VRP expression vector, the same replicon particle functions to deliver the antigen 
and to serve as innate immune-stimulant. On the other hand, in the VRP as adjuvant (GVI3000), 
the replicon particle only provides the danger signal function, while the antigen is not expressed 
from the replicon particle, but co-delivered as purified protein or inactivated virions. By 
separating the antigen delivery function from the adjuvant function in the GVI3000, we were 
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able to demonstrate the role of the adjuvant function in the VRP, and to start to understand how 
it mediates the changes in the quality and magnitude of the immune response in the neonate. 
In this thesis, using a neonatal mouse model, we showed that both platforms induced 
effective and protective immunity against two different infectious agents, influenza virus and 
dengue virus. Furthermore, VRP replicon particles served as useful tools to better understand the 
induction of the neonatal immune response.  
In summary, the VRP expression vector vaccines and adjuvants induced an adult-like 
adjuvant effect against dengue influenza antigens, and have the potential to improve the 
immunogenicity and protective efficacy of new and existing neonatal vaccines.  
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CHAPTER 1: INTRODUCTION 
 
1.1. Vaccination and Immunology 
1.1.1. Brief History 
The earliest recorded use of vaccination can be dated back to 1000 A.D. in ancient China, 
where individuals who were naïve to smallpox vaccination were inoculated with the content 
from smallpox vesicules, pustules or scabs (1, 2). Later records show this practice to be 
widespread in parts of Asia and North Africa (1, 3). The introduction of vaccination in England 
is credited to Lady Mary Wortley Montagu—the wife of English ambassador to the Ottoman 
Empire—who observed its practice in Constantinople in early eighteenth century (1). During that 
period, smallpox was the cause of 8-20% of all deaths in both rural and urban areas (4). 
However, it was well-known at the time that milkmaids who had shown signs of pox-like 
infection acquired from cows they milked, were well-protected from the worst symptoms of 
smallpox disease (1, 5). Edward Jenner, a rural physician in the late eighteenth century, used this 
knowledge to draw a link between the mild cowpox infection and protection from smallpox 
infection. 
In 1796, Jenner inoculated an 8-year old boy with cowpox virus taken from an infected 
milkmaid and challenged the child “some months afterwards” with smallpox (1, 4). The boy was 
protected and showed no sign of severe smallpox disease (4). The work of Edward Jenner was 
honored by Louis Pasteur—one of the most influential vaccinologist—by coining the term 
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vaccine (1). The work started by Jenner has led to smallpox being the only communicable 
disease to be completely eradicated from its natural environment (5). 
Following the example of Jenner, in 1881, Louis Pasteur observed that culture plates with 
Pasteurella septica, which causes a lethal form of cholera in chicken, left on the lab bench for 
two weeks, did not lead to illness in chickens (2, 3). In fact, the inoculated chickens were 
protected after infection with fresh P. septica cultures. This observation led to Pasteur’s 
conclusion that external insults can cause changes in bacteria leading to its attenuation but not 
any loss of immunogenicity (2, 3). Following these results, Pasteur replicated his success with 
vaccination against anthrax and rabies (1-3). In the twentieth century several pathogens were 
attenuated for vaccination, including Mycobacterium bovis by Calmette and Guerin in 1921 (6) 
and yellow fever virus by Max Theiler (7). It is a remarkable feat achieved by the pioneers of 
vaccination to have developed several highly effective live, attenuated vaccines given that the 
knowledge of pathogen and host immunity was so limited. 
 
1.1.2. Immune Response to Vaccination 
 The pace of vaccine development increased exponentially in the twentieth century 
resulting in vaccines against several lethal diseases such as diphtheria (1923), pertussis (1926), 
tetanus (1927), Influenza A (1936), paralytic poliomyelitis (1955), measles (1963), mumps 
(1967), rubella (1969), Haemophilus influenza type b (Hib) (1988), and Hepatitis A (1991) and 
B (1981) (2, 8). This could be partially attributed to the development of virus propagation in cell 
cultures by Hugh and Mary Maitland in 1928 (2). This and other advances have continued the 
pace of vaccine research unabated to this day. Widespread use of vaccines has been credited with 
increasing the human life expectancy in the 21st century (9, 10). The benefit of immunization is 
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especially evident in early life as it is estimated that early life immunization is saving 3 million 
children a year worldwide (4). It is estimated that approximately 80% of children were 
immunized at birth in 1990, up from 5% estimate in 1974 (4). However, many more lives could 
be saved if existing immunization programs were implemented properly (4). 
 Immune response to an effective vaccine is multi-faceted and complex. Our knowledge 
of how vaccines work is growing but still limited. Vaccines that are currently available were, for 
the most part, developed empirically with little understanding of the host immune response (11). 
The primary effector of vaccine-mediated immune response is antigen-specific antibody. 
However, several factors are important during an antibody response, including the quality, 
location, persistence etc. of antibody response. Persistence of antibody response underscores the 
important role B-cells play in effective immunity. Furthermore, T-cells also play an important 
role in the induction of high-affinity antibodies and immune memory, in addition to being direct 
effectors themselves. 
 
1.1.2.1. Antibody-response 
Vaccine-induced antibodies can mediate a protective immune response in the serum by 
minimizing or eliminating the spread of the pathogen systemically. IgG antibodies in the serum 
are primarily responsible for reducing the threat of viremia or bacteremia (12). The important 
role played by vaccine-induced systemic antibodies is evidenced by several examples. Hepatitis 
A virus infection has been shown to be prevented after passive administration of immune serum 
IgG in humans (13). In fact, if IgG is administerd during the incubation period of hepatitis A, it 
can reduce the severity of the disease and potentially convert clinical infections into subclinical 
incidents (14). Studies in non-human primates show that serum antibodies can protect from 
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paralytic poliomyelitis virus. Sera from a hyperimmune NHP was able to prevent virus spread to 
the CNS and reduce viremia in passively immunized animals, even though viral replication in the 
gut was no different from control animals (15). Several other studies also demonstrate the 
protective effect of systemic serum IgG including to pertussis (12), yellow fever virus infection 
(16), rabies virus infection (17), meningococcal polysaccharides (18), pneumococcal 
polysaccharides (19), and typhoid polysaccharides (20). Serum IgG against bacterial toxins, such 
as diphtheria and tetanus, have also been demonstrated to provide protection (21, 22). 
 Antibodies can also have a pathogenic effect as seen after dengue infection. Sub-
neutralizing antibody concentrations against an infecting dengue virus serotype can enhance the 
risk of severe dengue disease, such as dengue hemorrhagic fever or dengue shock syndrome (23-
25). Therefore, any live-attenuated vaccine design has to overcome this challenge by inducing 
protective antibody response against all four dengue serotypes simultaneously. Issues related to 
dengue vaccines are addressed in more detail below. 
 
1.1.2.2. Mucosal response 
Mucosal surface includes all of body’s mucus-covered epithelia that is exposed to the 
external world, such as those of respiratory, gastrointestinal, and urogenital tract as well as the 
exposed cornea/conjunctiva (26). These surfaces play a crucial role in preventing infections 
while simultaneously facilitating in the uptake of nutritional components and respiratory 
exchanges (27). In terms of surface area, the combined mucosal surface is the largest 
immunological organ of the human body and as such 90% of all infections initiate at the mucosal 
surfaces (26). In general, parenteral route of immunization does not lead to efficient mucosal 
immunity, even if the immunization leads to a systemic immune response (3). The two most 
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practical and effective ways of mucosal immunization are through oral and nasal routes (28). An 
example of an effective oral vaccine is OPV, which replicates in the gut and delivers antigen to 
the gut-associated lymphoid tissues (GALT), inducing a potent intestinal immune response. 
Immunization through nasal route has also been efficient, such as for cold-adapted influenza 
virus vaccine (29). 
 Although all antibody isotypes are present at the mucosal surfaces, IgA antibodies are the 
predominant isotypes in the mucosal secretion (30-32). The adaptive immune response at the 
mucosa initiates at the mucosal-associated lymphoid tissues (MALT), including the production 
of IgA-secreting B-lymphocytes (27). Furthermore, antigen transport to the MALT also starts the 
process of lymphocyte activation with effector functions at the mucosal surface (27). 
 
1.1.2.3. T-cell response 
Most current vaccines mediate protection through highly specific serum IgG antibodies 
(11). However, for some diseases such as tuberculosis, a passive antibody-mediated immune 
response is inefficient and T-cell induction by BCG vaccination is the primary effector of 
protection (33). There is evidence in other cases where vaccine induced T-cells contribute in 
mediating protection. Long-term protection in children immunized in infancy with pertussis 
vaccination seems to be from CD4 T-cells, after the antigen-specific antibodies have waned (34-
37). Measles immunization of infants is another example where antigen-specific antibody 
response is inefficient either due to immune immaturity of infant immune system or maternal 
antibody interference. Immunized children remain susceptible to measles infection, but are 
protected against severe disease, which is attributed to the induction of IFNγ producing CD4 T-
cells (38-40). These examples show that while prevention of infection can only be achieved by 
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antigen-specific antibodies, T-cells can prevent complications and reduce the severity of disease 
in their absence. Other examples where both vaccine-induced antigen-specific antibodies and T-
cells influence the outcome of infection are rotaviruses (41-43) and influenza viruses (44-46). 
 CD8 T-cells play a very important role in the clearance of virus- and bacterial-infected 
cells in chronic infections (47, 48). There are several examples where these cell-mediated 
immune responses can provide protection after primary infection or after reactivation from 
latency, such as varicella-zoster virus (49), herpes simplex virus type 1 (50), herpes simplex 
virus type 2 (51), Epstein-Barr virus (52), cytomegalovirus (53), and hepatitis C virus (54). 
 
1.1.2.4. Innate immune response 
The innate immune system plays a crucial first step in initiating the anti-pathogen 
immune response. Although it does not have the specificity or the memory of the T- and B-cells 
antigen receptors of the adaptive immune response, pattern recognition receptors (PRRs) of the 
innate immune response permit detection of a very wide range of potential pathogens (55). Both 
T- and B-cells employ multiple PRRs and utilize the cells and molecules of the innate immune 
system for their effector functions (55). PRRs, such as toll-like receptors (TLRs) in the 
endosome or RIG-I/MDA5 in the cytosol, control many DC functions and activate signals that 
initiate the adaptive immune response (56-58). In the context of vaccination, activating the 
appropriate PRRs and innate immune signaling is crucial in determining the strength, duration, 
and type of adaptive immune response. Live-attenuated vaccine approaches are usually the best 
inducers of humoral, cellular, and mucosal immune responses because they, like wild-type 
organism, can stimulate the innate immune response. However, for other gene-based vaccines 
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approaches, such as non-replicating antigens, an adjuvant is required for the stimulation of the 
innate immune system. 
 
1.1.2.5. Herd immunity 
Herd immunity is the common term applied to the concept that not all individuals in a 
given population have to be immune to a certain disease to protect all members (59, 60). 
However, there is an important distinction that should be made between herd immunity and herd 
protection (61). Herd immunity implies a secondary spread of attenuated pathogen to 
unimmunized individuals from those that have been immunized, as was observed with OPV (62). 
On the other hand, herd protection would mean that unimmunized individuals are protected or 
have a lesser probability of infection—due to immunized individuals in the population—without 
actually developing immunity against the pathogen (61). Regardless of the term used, herd 
immunity (or protection) is an important factor in any vaccine development and immunization 
program. Three factors that should be taken into account to develop herd immunity in a 
population prior to immunization are: the infectivity of the disease agent (highly infectious 
pathogens requires higher immunization rates), the vulnerability of the population (urban, 
crowded areas will require higher immunization coverage), and environmental factors (disease 
such as meningitis is more prevalent during winter months and hence require better protection 
during those months) (59).  
 
1.1.3. Early Life Immunology and Challenges 
The early life (<5 years) is an extremely sensitive period of human life in terms of 
mortality due to pathogenic infections (63-65). It is estimated that in 2012 approximately two-
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third of the mortality in children under the age of 5 years was due to infectious diseases (66). The 
burden of infectious diseases in newborns is especially high. The main underlying reason that 
makes newborns vulnerable to infections is their unique immune system which is adapted for 
postnatal life (67). Immunologically, humans are born with an immune system that favors 
tolerance at the cost of weak immune responses to infections, especially during the first month of 
life (neonatal) (68-70). The neonatal immune system gradually matures towards an adult-like 
immune system during infancy (<1 year of age). The susceptibility during neonatal and infant 
period could be due to the lack of immunological memory in the newborns. Research also shows 
that—compared to adults—newborns have: smaller number of immune cells in peripheral 
lymphoid tissues, qualitatively distinct immune cells, different proportion and phenotypes of 
immune cells and their subtypes, as well as deficiencies or “immune deviations” among APCs, 
T-cells, and B-cells (reviewed in reference (68)). When challenged with immune stimuli, 
children under the age of 2 months show TH2 cell polarization, weak TH1 polarization, and low 
innate antiviral type I IFN responses (71). Despite the unique nature of neonatal immune system, 
it is now believed that—given appropriate stimuli—neonatal immune system can mount at least 
a T-cell response which is comparable to an adult in vivo (72-74).  
 
1.1.3.1. Adaptive immunity 
Research in both neonatal mice (<7 days) and neonatal humans (<28 days) have shown 
that the T-cell-dependent and –independent antibody responses during this period is different 
from adults (reviewed in references (69, 70)). The antibody response in neonatal period is 
reported to be delayed, of lower magnitude, short-lived, qualitatively different (IgG2a in mice 
and IgG2 in humans are reduced indicating a TH2 bias), have lower average affinity, and reduced 
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heterogeneity (68). Maternal antibodies in human infants can further reduce the antibody 
response, most probably by removing the immunizing antigens (75, 76). 
 The differences in antibody response between an adult and neonate can be attributed to 
differences in either the B-cells or inadequate response by TH cells. B-cell population in neonatal 
spleen has been shown to be primarily immature, which fails to upregulate co-stimulatory 
markers such as CD86 and MHCII (69, 77). However, other studies have shown the neonatal B-
cells in the lymph nodes and the periphery tend to be more ‘mature’ and show less of the defects 
displayed by splenic B-cells (68, 78). Vaccines that target the B-cells in lymph nodes might 
induce adult-like antibody response in neonates (79). 
 There have been other explanations for the poor antibody response in neonates. In case of 
T-cell independent antigens, B-cells in the marginal zone are the primary responders in adults 
(80). However, marginal-zone B-cells are rare in neonatal spleens and appear at 1-2 weeks in 
mice and 1-2 years in humans, coinciding temporally with the acquisition of ability to mount 
antibody response to polysaccharide antigens (81-83). On the other hand, for T-cell dependent 
antigens, adult-like antibody response in neonates is possibly hampered by the absence—at 
birth—of three crucial splenic microarchitectural structures: lymphoid follicles, follicular-
dendritic-cell (FDC) networks, and germinal centers (84). These structures start developing after 
birth in a complex interplay of cytokines and lymphocytes with germinal centers appearing by 
the end of 3 weeks in mice, coinciding with the time when mice are capable of mounting adult-
like antibody response (85). In human infants, the germinal center appears around 4 months post-
birth (86). It can be concluded that the development process of microarchitectural structures, 
rather than any innate deficiency in the B-cells, might be the reason for deficient antibody 
response in neonates.  
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 Regardless of the pace of neonatal immune system development post-birth, it has been 
reported that antigen-specific memory B-cells can be induced in early life. Human infants when 
immunized with oral poliomyelitis virus (OPV) vaccine at three days old had very weak primary 
antibody response, which was significantly enhanced after a second dose two months later 
compared to unprimed infants (87). Similarly, antibody response to hepatitis B immunization 
showed memory response after the administration of the second dose (88). In contrast, tetanus 
toxoid immunization in human neonates did not show any antibody enhancement after booster 
shots during infancy indicating no memory response (89). Therefore, the development of 
memory B-cell response might be dependent on the antigen, the delivery system, or the adjuvant. 
 It is well established that the T-cell response in neonatal mice is biased towards TH2 cell 
lineage (68). However, well known promoter of a strong TH1 response, such as certain DNA 
vaccines and CPG motifs, have been shown to induce TH1 responses in neonatal mice (reviewed 
in references (90-92)). The bias towards TH2 immune response in human infants is not as clear-
cut as in neonatal mice (68). However, just as in neonatal mice, human infants are capable of 
inducing adult-like TH1-cell response to certain vaccines, such as for BCG (93, 94). Several 
reasons have been suggested for the apparent weak TH1 response and the TH2 bias of neonates. 
First, it has been shown that neonatal mice have at least 1-2 log reduction in total number of T-
cells compared to adult animals (72, 73, 91), which might reduce their protective capacity. 
Second, antigen load can also determine the TH response as reducing the antigen load of mouse 
leukemia virus from high to low switched the response from TH2 to TH1 (74). Third, the T-cell 
repertoire in neonates might affect the TH response as significant numbers of peripheral T-cells 
in neonates in the first few weeks of life are generated by hematopoietic cells of fetal origin, 
which typically mount a TH2 response (95-97). Similar results have been reported in human 
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neonates, where immune responses that develop to allergens in utero are TH2 (98-100). Finally, it 
has been suggested that upon re-exposure to antigens, TH1 cells from neonates undergo apoptosis 
skewing the TH response to TH2 (101).  
 For a long time, nenoates were thought to be deficient in CD8+ cytotoxic T lymphocyte 
(CTL) function (68). However, several studies have indicated that CD8+ CTL primary and 
memory response can be induced after a primary immunization in neonates: live replicating 
vaccines (74, 102-104), adult DCs (73), DNA vaccines (105-107), and oligonucleotides 
containing CpG motifs (108, 109). Human infants, congenitally infected with cytomegalovirus 
(110) or Trypanosoma cruzii (111), induce significant level of CTLs indicating that even in fetus, 
mature CTL activity is possible.  
 
1.1.3.2. Innate immunity 
Due to the absence of any immunological memory, neonatal innate immune system plays 
a crucial first step in initiating an immune response to pathogens or a vaccine. However, there 
are several differences between a neonatal and an adult innate immune system with important 
implications for the generation of an effective adaptive immune response. The predominant TH2 
microenvironment of the fetus influences the neonatal TH1/ TH2 profile by skewing the 
predominant response to TH2 (112, 113). In contrast to TH1 cytokines, The TH2 cytokines during 
pregnancy at the maternal-fetal interface are important for the success of pregnancy (114). The 
primary mechanism by which neonatal T-cells differentiate into TH2 cells is through secretion of 
high levels of IL-4 and low levels of IFNγ by TH1 cells (68, 115-118). IL-4, in both humans and 
animals, inhibits the expression of IL-12Rβ2 in naïve T-lymphocytes, which leads to the 
inhibition of TH1 response and the development of a TH2 response (117, 119). 
 
 12 
 The role played by the innate immune cells in shaping the immune response is critical 
and is summarized next. Neutrophils are the most numerous polymorphonuclear leukocytes and 
are one of the first cells to target and eliminate pathogens (120). Neutrophils are qualitatively and 
quantitatively deficient in early life compared to adults in the following ways: impaired 
neutrophil recruitment due to high levels of anti-inflammatory TH2 cytokine IL-6 in neonates 
(121), reduced phagocytic activity (122), reduced killing mechanism such as production of 
reactive oxygen species and antimicrobial proteins and peptides (123, 124), and diminished 
neutrophil rolling and adhesion, especially in preterm infants (125). 
NK cell subsets of the cellular immune response are another line of defense against 
pathogens, especially in viral infections (126). Functionally, NK cells are important for cytolytic 
action and IFNγ production. However, NK cell functions—degranulation and release of lytic 
factors—are reduced in early life (127). It has been proposed that increased level of TGFβ, 
through inhibition of transcriptional control factors T-bet and GATA-3 and promoting 
differentiation of Treg cells, is responsible for the suppression of NK cell function and enhanced 
risk of infection in early life (128, 129). 
It has been recently shown that immunosuppressive CD71+ erythroid precursor cells can 
impair neonatal host defense against infection (130). The authors demonstrated that the ablation 
of CD71+ erythroid cells in neonatal mice or their natural postnatal decline correlated positively 
with loss of immunosuppression, enhanced production of TNF upon stimuli by phagocytes and 
APCs, and increased resistance to pathogens, such as L. monocytogenes and E. coli. 
APCs are at the interface between innate and adaptive immune response. However, 
studies have shown that there are several differences between neonatal and adult APCs. Human 
cord blood cells show significantly reduced LPS-induced TNF secretion compared to adult 
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PBMCs (131). The early life APC cytokine response is distinct from adults in that there is a 
high-level expression of anti-inflammatory IL-6 and IL-10 as well as macrophage production of 
immunosuppressive IL-27 cytokine (132). As professional APCs, DCs are essential in directing 
the adaptive immune response (133). Studies primarily performed in murine models demonstrate 
qualitative and quantitative differences between adults and neonates (134). Ex vivo culture of 
neonatal mice splenic cDCs show lower expression of MHC class II, CD86 and cytokines such 
as IL-12p70, IFNγ, and antigen processing and presentation ability (135). While pDCs in human 
cord blood and adult peripheral blood are comparable in quantity, the amount of cDCs is 
significantly reduced (136). As was observed in murine models, neonatal cDCs in the human 
cord blood show impaired TLR-mediated IL-12p70 production (137, 138), while both cDCs and 
pDCs have reduced TLR-mediated multifunctional response (136). 
 
1.2. Need for Early Life Vaccines 
One of the eight goals of the United Nations’ Millennium Development Goals calls for 
reduction of mortality rate by two-thirds in children <5 years of age (65). Diarrheal and 
respiratory diseases caused by viral and bacterial pathogens are the common causes of mortality 
in early life (139). Additionally, malaria, tuberculosis, and HIV are also important childhood 
pathogens (140). Therefore, development of safe vaccines that can induce effective immunity to 
various infectious diseases soon after birth is a great public health challenge. 
 
1.2.1. Influenza vaccines 
Influenza is the most common cause of lower respiratory tract infections with 
approximately 48 million annual infection and 40,000 deaths (141). Influenza type A is the more 
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prevalent cause of morbidity and mortality, while influenza type B can cause regional epidemics 
of lesser severity than type A (142). Influenza virus initiates infection at ciliated columnar 
epithelial cells after breaching the mucous lining of the respiratory tract (143). The HA precursor 
protein cleaves into HA1 and HA2 by post-translational processing before membrane fusion 
(144). Although influenza infection is primarily targeted towards the trachea and upper 
respiratory tract, lung lesions can occur during a pandemic (145). The amount of virus produced 
is directly correlated to the extent and the severity of disease (142). 
 Immunity generated after a natural infection is primarily driven by serum antibodies as 
well as antibodies at the mucosal surfaces of the respiratory tract (142). Additionally, influenza 
specific T-cells play a role in the recovery (142). Finally, innate immune cytokines, such as 
interferon and other antiviral proteins also mediate protection from infection (142). 
 Licensed influenza vaccines are primarily of two kinds: live-attenuated and inactivated 
(146). Use of live-attenuated vaccine allows for a mimicking of a natural infection and the 
development of immunity against an attenuated viral strain, which minimizes the risk of a full 
blown infection (142). Inactivated vaccines are produced by inactivation of influenza virus with 
formalin or β-propiolactone followed by several purification steps to remove impurities (147). 
The effectiveness of influenza vaccines in preventing laboratory-confirmed symptomatic 
influenza varies form 50%-80% and depends on the age, immune status, and the relative 
similarity with the circulating strain (148). However, none of the currently available influenza 
vaccines are recommended for use in infants <6 months old (146). Additionally, although live-
attenuated have been shown to be more effective in children 6-11 months old compared to 
inactivated vaccines, they have also been associated with safety concerns, such as increased rate 
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of wheezing and hospitalization (149, 150). There are currently no adjuvants included in licensed 
inactivated influenza vaccine formulations that can improve immune responses (147). 
 
1.2.2. Dengue vaccines 
Dengue virus (serotypes 1-4) is the cause of the leading mosquito-borne viral disease in 
the tropics and sub-tropics, with an annual estimate of approximately 390 million infections 
(151). Up to half a million people are hospitalized every year with severe dengue disease 
(Dengue Hemorrhagic Fever/Dengue Shock Syndrome; DHF/DSS), including a large proportion 
of children (152). Each dengue serotype can cause mild to severe disease. Additionally, infection 
with one serotype induces life-long immunity to that dengue serotype but short-lived immunity 
against other serotypes. As the immunity declines, the presence of non-neutralizing dengue 
antibodies becomes a risk factor for DHF/DSS. DHF/DSS occurs after primary infection in 
infants born to dengue-immune mothers (24) or upon a secondary heterotypic infection in older 
individuals (25). The leading hypothesis to explain DHF is the presence of sub-neutralizing 
antibody levels, which leads to an enhancement of dengue virus infection of Fc-receptor-bearing 
cells (also known as antibody-dependent enhancement) (23). 
 Neutralizing antibodies are thought to be the primary correlate of protection through 
prevention of host cell binding and target cell infection (153). However, a recent study reported 
that CD8+ T-cells correlated positively with protection in an HLA-specific manner (154). There 
are other considerations in designing and administering an effective dengue vaccine. Firstly, any 
effective dengue vaccine must be tetravalent and induce equivalent neutralizing antibody 
response to all four serotypes because of theoretical enhanced risk of severe disease if 
incomplete immunity is induced to one of the four components. Secondly, tetravalent vaccines 
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should avoid serotype interference whereby a dominant serotype in a live attenuated vaccine 
prevents other serotypes from inducing an effective immunity. Reports have described such 
serotype interference resulting in an unbalanced antibody response and need for additional 
immunizations to achieve a tetravalent response (155). Finally, vaccines that are targeted towards 
children <1 year old should also address the issue of maternal antibody interference that can 
occur if live attenuated vaccines are administered in children born to dengue-immune mothers 
and presumably have passively transferred antibodies. 
Currently, there are no licensed dengue vaccines. However, several live attenuated 
vaccines are in various stages of clinical trial [concisely reviewed in (156)]. A point to note is 
that none of the vaccines in clinical trials are being promoted for use in children <1 year due to 
the various issues addressed above. 
 
1.3. Current Vaccine Technologies 
 Most licensed vaccines fall into three categories: live attenuated (LAV), inactivated 
pathogen, and subunit/protein derived from infectious organisms (Table 1.1). Although some of 
them, like polio or smallpox and others, have been extremely efficacious, these vaccine 
technologies have not completely eliminated the threat of morbidity and mortality from 
infectious diseases. It is estimated that currently infectious diseases account for approximately 
25% of all mortality (157). Therefore, there is a need for the development of vaccines against 
other pathogens and advancement of gene-based vaccines by improving DNA vaccines, vectored 
vaccines, and adjuvants for non-replicating antigens. 
 
 17 
Table 1.1 - Current vaccine platforms 
 
1.3.1. Live-attenuated vaccines 
LAVs are essentially a weakened form of the pathogenic bacteria or viruses generated in 
the lab. Although the LAVs were originally designed through serial in vitro passage or random 
chemical mutagenesis without knowing its effects or risk of reversion, more recent designs 
includes removing one or more genes that encode virulence or metabolic factors (158). Their 
design reduces the risk of symptomatic disease, while mimicking a natural infection. Therefore, 
they elicit a long-lasting potent humoral, cellular, and mucosal immune response, often after one 
or two dose(s). Despite its advantages, LAVs have poor stability, ability to revert to the 
pathogenic strain, and may cause complications in immune-compromised individuals. Some of 
the infectious diseases that have been successfully immunized against using LAVs are smallpox, 
oral poliomyelitis, mumps, rubella, influenza, etc. 
  
TABLE 1.1. Current vaccine platforms 
Vaccine platform Benefits Limitations Examples used in humans 
Live attenuated Low cost 
No adjuvant needed 
Highest immunogenicity 
Humoral, cellular and mucosal 
Long-lasting immunity 
Poor stability 
Possible reversion to pathogenic 
May be harmful in immune-compromised 
Smallpox, oral polio, measles, 
mumps, rubella, hepatitis A, 
yellow fever, rotavirus, 
influenza 
Inactivated Better stability 
Safer, absent reversion 
Higher cost 
No cellular or mucosal immunity 
Adjuvant needed 
Short lasting immunity 
Booster required 
Influenza, polio, Japanese 
encephalitis, Tick-borne 
encephalitis, rabies 
Subunit and Virus-
like particles 
Safe 
Multimeric antigen 
Higher cost 
Adjuvant needed 
Hepatitis B, human 
papillomavirus 
Live recombinant 
vectors: 
    Poxvirus 
    Adenovirus 
    Alphavirus 
    Others 
Very immunogenic  
Humoral, cellular and mucosal 
Safe (non-propagating vectors) 
Ineffective in the presence of pre-existing immunity In clinical trials 
DNA-based Antigens presented in the 
context of MHCI 
Limited immunogenicity In humans 
Integration into the host genome is a potential risk 
Not licensed for human use 
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1.3.2. Inactivated vaccines 
Inactivated vaccines are produced after the pathogen is killed with chemicals (such as 
formalin), heat, or radiation. Because the pathogen is killed, there is no chance of reversion in 
inactivated vaccines. Additionally, these vaccines are very stable and can easily be stored. 
However, unlike LAVs, inactivated vaccines are not very immunogenic and require adjuvants to 
boost the immune response. Furthermore, immunization with inactivated vaccines may require 
multiple doses to maintain immunity. Inactivated vaccines that have been used in humans 
include influenza, polio, rabies, etc. 
  
1.3.3. Subunit vaccines 
Another class of vaccines is termed subunit vaccines, as they only contain antigens 
derived from a pathogen that best stimulate the immune system and not the entire pathogen. 
Therefore, subunit vaccines have even lower risk of adverse reaction. However, the process of 
determining the most immunogenic antigens and epitopes of a pathogen is a very time 
consuming and expensive process. Furthermore, subunit vaccines require adjuvant for efficient 
priming and induction of immune response. Hepatitis B is an example of subunit vaccines that 
have been approved for human use. Human papillomavirus vaccines (Gardasil and Cervarix) can 
also be categorized with subunit vaccines as they only contain the surface glycoproteins that 
interact to form virus-like particles. 
 
1.3.4. DNA vaccines 
Although they have been a relatively recent development, DNA vaccines have shown to 
be relatively safe and able to induce both humoral and cellular immunity in small rodents and 
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non-human primates (159, 160). Studies in humans have shown that DNA vaccines can induce a 
potent CTL response against malaria (161). DNA vaccines are also considered relatively stable 
and more cost-effective during manufacturing and storage (162). Other advantages that a DNA 
vaccine has includes the ability to immunize against multiple antigens using a single plasmid 
(162) and the stimulation of the innate immune system through the activation of TLR9 by 
unmethylated CpG motifs present on bacterial plasmid DNA (163). Finally, DNA vaccines can 
be advantageous in neonatal immunizations where passively transferred antibodies of maternal 
origin can interfere with vaccines, if the maternal antibodies recognize presented antigen (164). 
However, there are some limitations to DNA vaccines. DNA vaccines require a large dose to be 
effective in inducing immune response (162). Additionally, DNA vaccines are usually 
administered intramuscularly, which are effective in small animal models; however, they have 
been relatively inefficient in the induction of antibody response in humans and non-human 
primates (162).  
In addition to the current vaccine technologies described above, viral expression vector 
vaccines have been extensively studied. Below we will describe in detail the use and effect of 
these potential vaccine candidates. 
 
1.3.5. Viral expression vectors 
One of the primary interests in vaccinology has been to understand the induction of 
immune response after a natural infection and mimic those after immunization. Towards that 
end, vaccinologists have used viruses as a tool for probing the immune system as well as for 
immunization. The advantage of using viruses for immunization is based on the fact that viruses 
have evolved to develop structures and mechanism that are highly effective in infecting cells, 
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expressing viral proteins, and sometimes replicating to high titers. These viral vector vaccines 
are generated using molecular genetic approaches and use their efficient cell entry and 
replication mechanism to express heterologous genes, which then act as the immunizing antigen 
[reviewed in (165-167)]. Vaccines that use bacterial genome as expression vectors have been 
reviewed elsewhere (168, 169). There are many examples of viral expression systems. Below we 
will focus on three of the most studied systems: poxviruses, adenoviruses, and alphaviruses. 
 
1.3.5.1. Poxviruses 
Poxviruses are linear, double-stranded DNA viruses that are relatively large with genome 
size of approximately 200,000 base pairs (170). As virus expression vectors, poxviruses have 
several advantages. First, poxvirus vaccine vectors are very stable and retain immunogenicity 
upon lyophilization, which overcomes an important hurdle in immunization, especially in the 
poor, developing world (171). Second, poxviruses can be easily genetically manipulated and can 
incorporate large amount of multiple foreign DNA, making them cost-effective (170, 172). And, 
thirdly, poxvirus vaccine vectors are quite versatile as they can induce effective immunity 
through multiple routes of immunization (170). 
 Preexisting immunity is a concern for any viral vector vaccine and so it is true for 
poxvirus vectors. However, in the case of vaccinia virus, individuals under the age of 30 are 
generally vaccinia-naïve, due to the cessation of smallpox vaccination in the early 1970s (170). 
Additionally, systemic immunity to poxvirus can be overcome through the mucosal delivery as 
the mucosal and systemic immune systems are distinct (171, 173, 174). As with most viral 
vaccine vectors, one of the most common ways to minimize the effect of preexisting immunity 
has been to implement a heterologous prime-boost strategy, and hence has been suggested for 
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poxvirus immunization as well. There are several poxvirus vaccine vectors, but the two most 
well known are modified vaccinia Ankara (MVA) (175) and NYVAC (based on the Copenhagen 
strain) (176). 
 Poxvirus vaccine vectors have been shown to be effective inducer of humoral and cellular 
immunity, including upon mucosal delivery (177). In several studies, poxvirus vaccine vectors 
induced significant immunity to several infectious diseases, including influenza (178), measles 
(179), SHIV (180). The potential of poxvirus vaccine vectors should be further pursued. 
 
1.3.5.2. Adenoviruses 
The adenoviruses (Ad) are non-enveloped icosahedral virus with linear, double stranded 
DNA genome of 36 kb length encoding more than 30 proteins (171, 172, 181). Ad have a variety 
of attractive features that make them attractive candidates for vaccination: stability (because they 
are naked, non-enveloped), ease of manipulation, growth to very high titers (purified up to 1012 
particles per ml), simple purification, broad tissue tropism, and they do not integrate into the host 
genome while existing extra-chromosomally (171, 181). Similar to poxviruses, Ad retain 
immunogenicity after lyophilization and can be delivered through all routes of immunization 
(171). While replication-competent Ad vectors are useful where viral replication is desired for 
high expression of immunogen using low doses, replication-incompetent Ad vectors can also 
achieve robust immune response albeit with high dose vaccination (181). Replication-
incompetent Ad vectors are designed with either lack of structural genes in the genome or 
mutations in the structural components (182). 
 Currently, there are 51 serotypes with six species described for Ad, with Ad2 and Ad5 
causing approximately 5-10% of all upper respiratory tract infections reported in children (172). 
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Because they are so prevalent, pre-existing immunity could be a concern for Ad vector 
immunization. Additionally, Ad vectors, especially replication-competent, have limited capacity 
to carry heterologous antigens (165). Inflammation in the host due to induction of multiple 
signaling pathways can lead to dose-dependent toxicity (181). Also, at high multiplicity of 
infection replication-defective Ad vector can self-replicate, leading to further inflammation and 
tissue damage (183). Researchers have suggested use of different Ad strains to circumvent pre-
existing immunity as well as oral inoculation to minimize the potential of a systemic hyper-
inflammation (165, 171). Ad vectors have been demonstrated to be effective in rodent and NHP 
models against several pathogens, such as malaria (184), Ebola (185), SHIV (186), measles 
(187), and certain cancers (188). Due to the potential that Ad vector vaccines hold in the 
treatment of both infectious diseases and cancers, further studies should continue towards 
developing new candidate vaccines. 
 
1.3.5.3. Alphaviruses 
Alphaviruses have a small genome (approximately 12 kb in length), and are single 
stranded, positive sense, RNA viruses belonging to the Togoviridae family. Due to their 
relatively small size and icosahedral nucleocapsid, the heterologous gene sequence that can be 
added to alphavirus vectors is limited, with heterologous genes of 1 kb length are stable upon 
viral passage (189). Three alphaviruses, Sindbis virus (SIN), Semliki forest virus (SFV), and 
Venezuelan equine encephalitis (VEE) have shown potential as expression vector vaccines 
against infectious disease and cancer (reviewed in (190-196)). Both propagation competent and 
propagation defective alphavirus vectors have been designed and studied. In the propagation 
defective alphavirus vectors, the replicon genome with structural genes substituted by an 
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immunizing gene, is packaged into virions which can infect cells but not produce new virus 
particles (190). 
 Alphaviruses vectors are highly immunogenic as they express high levels of heterologous 
antigens and by targeting DCs (197, 198) induce potent humoral, cellular, and mucosal immunity 
(190-196). Additional advantages of Alphaviruse vectors are their ability to induce innate 
immune signaling and relative absence of preexisting immunity in the general population (167, 
199). Some of the protective immune response that have been demonstrated include against 
influenza virus (200-202), Ebola virus (203), and SIV (204, 205). A detailed discussion of one of 
the alphavirus replicon vector, VEE, is presented below in detail. 
 
1.3.6. Adjuvants 
The first instance of adjuvant use was done by Ramon in 1925, when it was demonstrated 
that it was possible to increase antigen-specific levels of diphtheria or tetanus anti-toxin levels by 
adding bread crumbs, tapioca, agar, starch oil, lecithin, or saponin [reviewed in (206)]. The few 
adjuvants that are currently in use, such as aluminum salts and oil-in-water emulsions, were 
developed empirically and there is still much to be discovered about their mechanism of action 
(207). However, effects of numerous adjuvant candidates have been described in humans: 
improved vaccine efficacy, increase in humoral and T cell response, longer duration of protective 
effect, increased cross-protection within a pathogenic strain or between strains, antigen dose 
sparing, reduced number of vaccine doses to reach protective threshold, and modulating the 
antibody isotype response as well as T-cell (TH1, TH2, TH17, etc.) responses (208). Adjuvants 
can be subdivided into several general categories: mineral salts, oil-emulsion, plant derivatives, 
microbial derivatives, particulate, endogenous immunostimulant, and synthetic (Table 1.2). We 
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introduce VEE replicon-based adjuvant as a new category of bio-adjuvant. Below, we will 
briefly introduce a few examples of some of the above listed adjuvant categories.  
Table 1.2 - Current adjuvant technologies 
 
1.3.6.1. Mineral salts (Alum) 
Aluminum-based mineral salts, or alum, have been in use for almost a century and are the 
only adjuvants approved for use in licensed human vaccines by the FDA in the U.S. (206). The 
mechanism of action of alum is still in debate. However, it has been suggested that alum 
mediates its effect through “depot” effect, whereby antigens are retained in alum-induced 
(together with clotting agent fibrinogen) depot at the injection site and released slowly (209, 
210). However, it has also been recently demonstrated that upon vaccination in fibrinogen-
deficient mice, although alum depots were not formed, the antibody response was comparable to 
wild-type mice (210). This study shows that alum depots are dispensable for the adjuvant effect 
of alum, although it is still possible that alum can form “antigen depots” in the draining lymph 
nodes following transport from the site of immunization (211). The primary effect of alum is to 
regulate TH1/ TH2 environment (212) by promoting TH2 cytokines, in particular IL-4, and 
TABLE 1.2. Current adjuvant technologies 
Type of Adjuvant General Examples Specific Examples (brand name) Mechanism of action 
Mineral salts Aluminum hydroxide Aluminum phosphate 
Alhydrogel (Alum) 
Adju-Phos Depot 
Emulsion – Oil in Water Freund’s Incomplete adjuvant Montanide ISA 51 Depot 
Emulsion – Water in Oil Saponins QS-21 Depot 
Microbial derivatives  
Bacterial DNA 
Bacterial exotoxins 
Endotoxin-based adjuvants 
CpG oligonucleotides [TLR9] 
Cholera toxin (CT) 
Monophosphoryl lipid A (MPL) [TLR4] 
Immunostimulatory 
Particulate Immunostimulatory complex (ISCOMs) Virosomes, Liposomes, Proteosomes 
ISCOMATRIX 
 Immunostimulatory 
Endogenous 
immunostimulant Cytokines IL-2, IL-12, IFNγ Immunostimulatory 
Synthetic Pathogen-Specific 
Molecular Pattern based 
Adjuvants 
Imidazoquinoline-like molecules 
Synthetic polynucleotides 
Imiquimod [TLR7], Resiquimod [TLR7/8] 
Poly A:U, Poly I:C [TLR3] Immunostimulatory 
Bio-adjuvants VEE replicon particles (?)  Mimics early events of natural infection 
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improving TH2 IgG subtype, which is IgG1 in mice (213, 214). It has been recently shown that 
the mechanism of alum innate immune activation goes through NLRP3 inflammasome activation 
(215, 216). Further investigations demonstrated that the initial activation of the TH2 immune 
response by alum occurs through PI3 kinase activation and subsequent inhibition of IL12p70 
secretion by DCs, a key cytokine that drives naïve TH response towards TH1 (217). Although 
there has been tremendous amount of discovery in alum adjuvanticity, further research is needed 
to understand the immunomodulatory effects of alum compounds and the protective antibody 
response it elicits. 
 
1.3.6.2. Emulsion (Freund’s Adjuvants) 
Freund’s adjuvant—incomplete (IFA) and complete (CFA)—were discovered over 50 
years ago and have been experimentally used in various studies (218). However, much remains 
unknown about its mode of immune activation. While IFA is composed of a paraffin oil 
surfactant mixture that forms a water-in-oil emulsion when mixed with an antigen, CFA 
additionally contains heat-killed Mycobacterium preparation, which further increases its 
immunogenicity (218). Both IFA and CFA induce potent humoral response, but only CFA 
induces cell-mediated immune response, suggesting that the Mycobacterium preparation drives 
the that response (218). Furthermore, the cytokine profile in CFA is more TH1 than IFA (219). 
 There are some serious concerns with regard to the safety of both IFA and CFA as they 
have been associated with moderate to extreme local inflammation upon immunization in animal 
models and human subjects (218, 220). They have also been associated with the formation of 
granulomas or tubercles, which was dependent on the induction of TNF by the adjuvant (218, 
 
 26 
221, 222). Although potent adjuvants, safety concern should be further addressed before 
Freund’s adjuvants can be a candidate for human vaccination. 
Saponins are triterpene glycosides obtained from the bark of Quillaja saponaria Molina 
tree, which are native to South America (223). Quil A is a partially purified saponin used as 
adjuvants in veterinary vaccines (224). Quil A has also been used as a component of immune-
stimulating complexes (ISCOMs), which are small (40nm), cage-like particles additionally 
containing cholesterol and phospholipids (225). Although ISCOMs are very potent adjuvants, 
there are some safety concerns due to toxicity of Quil A in mice (225). Nonetheless less toxic 
saponins as part of ISCOMs are in development for human use (226). 
 
1.3.6.3. Microbial derivative (CpG) and other TLR ligands 
CpG motifs are considered pathogens associated molecular patterns (PAMPs) because 
they are ubiquitous in microbial genome but rare in vertebrates (227). They are very potent 
adjuvants of innate immune system inducing protection in both rodents and primates (163, 228). 
CpG are TLR agonists that activate TLR9. Just as any other TLR agonist (except for TLR3), 
TLR ligation initiates a complex signaling pathway involving MyD88, resulting in transcription 
factor NF-kB activation and the release of pro-inflammatory cytokines IL-6, IL-12, and TNF-α 
(229, 230). Immune effect of CpG includes increased cellular migration towards draining lymph 
nodes (231), higher expression of DC co-stimulatory markers (232), higher cytokine production 
(233), production of IgG2a antibodies (234), and enhanced cell-mediated immune response 
(206). In summary, CpG are a promising candidate as adjuvants due to their potent immune 
response. 
Other TLR ligands have been unwittingly used in vaccines for decades, evidenced by the 
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fact that vaccines containing bacterial cell walls, bacterial DNA, or viral RNA, can engage 
distinct TLRs and activate immune cells (235). Specific microbial molecules have been defined 
as ligands for these TLRs: lipopolysaccharides (LPS) (recognized by TLR4), flagellin (TLR5), 
and single (TLR7/8) or double-stranded RNA (TLR3) (236). 
 
1.4. Venezuelan Equine Encephalitis Virus (VEE) 
 Venezuelan equine encephalitis virus (VEE) is a single stranded positive-sense RNA 
virus of the genus alphavirus and family Togoviridae. While alphaviruses are mosquito-borne 
infections, VEE is maintained in nature in an enzootic cycle between mostly Culex mosquitoes 
and small rodents (171). Alphaviruses are divided into two groups, Old World and New World 
viruses depending on their geographic origin. VEE is considered a member of New World 
alphavirus as it is endemic in Central America and the northern regions of South America and 
represents a significant burden of disease in these regions. The Old World alphaviruses, such as 
Sindbis virus (SIN), Semliki Forest virus (SFV), Ross River virus (RRV), Chikungunya virus 
(CHIK), and O’nyong-nyong virus (ONN) cause a somewhat different disease with arthritic 
and/or arthralgic symptoms, as well as fever and rash (237). 
VEE was first isolated from infected equine brains in 1938 with the first documented case 
of human infection reported in the 1950s (238). VEE has caused sporadic outbreaks of febrile 
and neurological disease in both human and equid population throughout the past century (238). 
While the case mortality in humans is 0.5-1%, in equid populations, the case mortality can be as 
high as 50% (239). Early attempts to prepare vaccines through formalin inactivation of VEE 
were unsuccessful until the development of live-attenuated TC-83 vaccine in 1961 (240). TC-83 
was prepared by passaging the virulent IAB strain 83 times in cell culture of guinea-pig heart 
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cells (240). TC-83 and its inactivated version C-84 have been used to vaccinate equines and 
humans with TC-83 proving to be extremely immunogenic (238). Due to the potential of 
outbreaks and its use as an agent of biological weapon (238), VEE biology has been extensively 
studied. 
 
1.4.1. VEE Genome and Replication 
VEE is a single stranded, positive-sense RNA virus with a genome of approximately 11.5 
kb length capped with a 5’ terminal 7-methylguanosine and 3’ polyadenylated tail (241). The 
genome is divided into two regions: 5’ two-third contains the viral non-structural proteins (nsp1-
4) in a single open reading frame, while the 3’ one-third contains the structural components 
(capsid, E2, 6K, and E1 proteins) on a second open reading frame expressed from a subgenomic 
26S promoter (242). There are four conserved sequence elements (CSE), important for 
replication, spread throughout the genome: two near the 5’ end, one between non-structural and 
structural gene cassettes, and one immediately upstream of poly-A tail (243). Additionally, one 
short non-translated region (NTR) at each 5’ and 3’ terminal ends are also important for 
replication (242). VEE genome is encapsidated in an icosahedral nucleocapsid surrounded by 
envelope containing spikes formed from trimers of glycoproteins, E1 and E2, heterodimers 
(242). While the molecular mechanism of VEE replication is relatively understudied, other 
alphaviruses, especially SIN and SFV, have been extensively studied. The review below 
summarizes the findings in other alphaviruses with VEE mentioned where appropriate. 
 The receptor for VEE attachment is currently unknown with c-type lectins (244), laminin 
receptor (245), and heparin receptor (HS) proteoglycans (246) proposed as candidates. Recently, 
natural resistance-associated macrophage protein (NRAMP) has been suggested as the cellular 
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receptor for SIN in both mammalian and insect cells (247). However, the authors also reported 
that RRV infection was NRAMP-independent, indicating that alphaviruses might use diverse set 
of receptors. Studies have indicated that E2 protein mediates attachment followed by entry 
through virus-cell membrane fusion in the early endosome. The fusion is mediated at low pH via 
a hydrophobic amino acid sequence in the E1-protein. Viral nucleocapsid release into the host 
cytoplasm occurs immediately after the receptor-mediated endocytosis (242). A viral fusion-
independent entry mechanism has also been suggested for SIN, whereby following attachment 
the virus directly releases its genome into the plasma membrane without inducing membrane 
fusion or disassembling the viral protein shell (248). 
 Since alphavirus genomic RNA acts as a messenger RNA, immediately after release into 
the cytoplasm, the host translation machinery translates the viral genome into the precursor P123 
or P1234 (249). The predominant species produced is P123, while 10-20% readthrough of the 
opaI codon at the nsp3-nsp4 junction produces P1234 polyprotein in SIN (242). The P1234 
polyprotein is rapidly cleaved at the nsp3/4 junction by the cis-acting domains in nsp2, resulting 
in P123 and nsp4 production (242). Minus sense RNA strand is produced from a complex of 
P123 polyprotein and free nsp4, the viral RNA-dependent RNA polymerase, initiating at the 3’ 
CSE of the parental genome within 3-4 hours of infection (242). The production of minus strand 
is rather limited, due to the presence of few parental genomes and limited nsp4 quantity (250). 
Subsequently, P123 polyprotein is cleaved at nsp1/2 and nsp2/3 junctions yielding nsp1, nsp2, 
and nsp3 (251). Production of the nsp1-3, together with nsp4, irreversibly shifts the viral 
machinery to start the production of positive-sense genome (252). This leads to the production of 
two RNA species using two different promoters: 49S located in the 3’ NTR of the minus strand 
produces full-length genomic RNA and the 26S located in between nonstructural and structural 
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gene cassette yields subgenomic RNA (242). The subgenomic RNA is produced in a 5-10 fold 
molar excess of the genomic RNA ensuring adequate production of structural components for 
assembly of new virions (242). 
 The translation of subgenomic RNA produces structural polyprotein capsid-PE2-6K-E1 
followed by immediate cleavage of the capsid protein. The capsid protein binds the genomic 
RNA at the encapsidation signal (253). One molecule of genomic RNA interacts with 240 copies 
of the capsid protein in the cytoplasm to form the nucleocapsid (238).The rest of structural 
polyprotein (PE2-6K-E1) then translocates to the ER (254). After folding and conformational 
changes, the viral E1 and E2 are glycosylated (255). Subsequently, the viral glycoproteins egress 
from the ER into the Golgi network followed by passage into trans-Golgi network, where furin 
cleavage of PE2 yields mature E2 glycoproteins (256). Initiation of virus budding occurs when 
nucleocapsids, which diffuse throughout the cytoplasm, encounter and bind the E2-E1 complex 
at the plasma membrane (257). Overall, the alphavirus infection process leads to inhibition of 
host RNA production, protein synthesis, and eventual apoptosis (237, 258). 
 
1.4.2. VEE pathogenesis 
VEE infection in equines and humans leads to a range of symptoms, from asymptomatic 
to acute and fatal encephalitis (238). Some of the factors that affect disease severity are patient 
age, immune status, and the virus serotype (259). The incubation of VEE can last from 2-5 days 
with symptomatic infections resulting in some of the following symptoms: fever, chills, malaise, 
myalgia in the thigh and back, nausea, vomiting, and severe retro-orbital or occipital pain. These 
symptoms subside within a week in the majority of cases; however, severe infections can result 
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in convulsions, stupor, and coma. Death occurs in <1% of cases accompanied by diffuse 
congestion and edema with hemorrhage in the brain, lungs, and GI tract (260). 
 Infection of rodents with VEE has yielded many similarities between the observed 
pathogenesis to those observed in humans and equines (261, 262). Because of the ease of 
handling mouse as well as the availability of molecularly cloned VEE and non-propagating VEE 
replicon particles (VRP), mice have been widely used to understand VEE pathogenesis (198, 
263-266). VEE exhibits a biphasic disease in mice, similar to the pattern in equines, with an 
initial lymphotropic phase replication in the peripheral lymph nodes followed by infection of the 
CNS (neurotropic phase), which leads to lethal encephalitis by day 6-8 (261). Biphasic infection 
of VEE using both virulent and molecularly cloned mutants has been unequivocally 
demonstrated in mice (263, 266, 267). 
 The early steps in the pathogenesis of VEE and induction of innate immune responses by 
VEE were discovered using VRPs, which are single-replication cycle, propagation-incompetent 
virus particles. Using VRP expressing GFP (GFP-VRP), initial target cells were identified as 
Langerhan cells, as they stained positively for DEC-205 and MHCII (198). Due to the 
morphological similarity of the infected cells to DCs, the authors concluded that DCs appear to 
be the primary target of VEE infection. Furthermore, Tonkin et al. demonstrated that DCs were 
sufficient for the immune activity of VRP, with monocyte-derived inflammatory DCs (iDC) 
most frequently targeted and most dramatically recruited in the draining lymph nodes of mice 
(268). VRP infection of DCs has been demonstrated to occur at the site of injection followed by 
rapid transfer (approximately 4 hours) of the infected DCs to the DLN and replication in the 
DLN as early as 6 hpi (267). It is suggested that VRP can also travel through passive lymphatic 
drainage to the DLN and infect recruited inflammatory DCs (268). Early replication of VEE in 
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the DLN leads to viremia, which peaks at around 12 hpi with multiple organs infected by 18 hpi, 
including the spleen, heart, lung, and kidney (267). Peripheral titers peak between 24-48 hpi 
followed by CNS infection through the olfactory neuroepithelium and the trigeminal nerve (264, 
266, 267). 
 Innate and adaptive immune responses have been important in host response to VEE 
infection. Induction of robust systemic IFN-α/β occurs within 6 hpi, although its exact 
mechanism is not known (269-271). The average survival time of IFN-α/β-receptor deficient 
mice infected with VEE was reduced to 30 hours from 7.7 days in wild-type control, possibly 
due to an inability to control viral replication and dissemination into the periphery (271). The 
complement system also plays an important part in the clearance of VEE from the periphery and 
prevents CNS invasion in mice (272). Antibodies play an important protective role in anti-VEE 
immunity, with both VEE-specific IgM and IgG able to clear virus form the periphery (269). 
However, antibody response initiated during the primary immune response was not sufficient to 
prevent invasion of the CNS and lethal outcome in mice (237). Finally, the anti-VEE T-cell 
response has been shown to be crucial in the recovery from VEE-induced encephalomyelitis with 
IFNγ producing CD4+ T-cells more effective than CD8+ T-cells (273). 
 
1.4.3. VEE-based vaccine vectors 
Many insights about VEE-host interactions have been gained after the development of a 
full-length infectious cDNA from viral genomic RNA isolated from the Trinidad Donkey strain 
(201, 274, 275). This cDNA was cloned into a plasmid, pV3000, which can be in vitro 
transcribed to obtain full length, infectious RNA. The RNA can then be used to produce virus 
(V3000), which should be genetically identical to TD VEE strain, through electroporation into 
 
 33 
permissive cells. This easy-to-use, reverse genetics system can be further used to generate VEE 
vectors to deliver heterologous antigens, including two vectors that have been described. The 
first is termed double promoter vector and contains a second 26S subgenomic promoter 
downstream of the original 26S subgenomic promoter with structural genes (200). These 
propagation-competent vectors allow for the expression of a foreign antigen from the second 26S 
promoter and induce strong humoral and cellular immune responses in the infected cell (200). A 
second VEE vector utilizes the reverse genetic system to replace the viral structural genes with a 
heterologous antigen and is called VRP. The VRP vectors are capable of infecting target cells, 
undergo a single round of replication, and do not propagate beyond the first infected cell as they 
can’t produce new virions due to the lack of structural genes in their RNA genome (201). It has 
been shown that VRP immunization induces protective immunity in rodent models of anthrax, 
botulism, Whipple’s disease, Lassa fever, Ebola, influenza, and human papillomavirus (202, 203, 
276-281). Additionally, in non-human primate models, VRP immunization generated protective 
immunity against Marburg, Ebola, smallpox, dengue virus, and SIV (156, 204, 282-285).  
 VRP vectors are packaged using two helper RNAs supplied in trans, expressing the 
capsid and the glycoproteins and lacking the packaging signaling, together with the replicon 
transcript. While the replicon genome allows for the reproduction of the replicon RNA itself as 
well as the helper RNAs, the helper RNAs produce the structural proteins necessary for virus 
packaging. Since only the replicon genome has the packaging signal, released VRPs contain only 
the replicon RNA and not the helper RNAs. Additionally, the highly expressed transgene in the 
packaging cells are excluded from VRP as its assembly only includes the alphavirus structural 
proteins with the virus-specific packaging signal. 
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1.4.4. VEE-based adjuvants 
VEE-based adjuvants are related to the VRP vectors described above and are generated in 
a similar way. GVI3000 (previously known as nVRP) is a virus like particle that is generated by 
complementation of replicon RNA, which has the 26S subgenomic promoter and the structural 
genes deleted, together with the two helper RNAs (286). Just like the VRP vectors, GVI3000 
particles do not propagate beyond the first infected cell and hence function as a first-in-class 
biological adjuvant. GVI3000 functions by inducing a strong natural and self-regulated innate 
immune response in the draining lymph node, which leads to an induction of immune response 
against the co-delivered killed virus antigen or the soluble protein antigen (287). The ensuing 
adaptive immune response towards the co-delivered antigen is comprehensive (humoral, cellular, 
and mucosal) and long lasting. Adjuvant studies using GVI3000 in mouse model induced robust 
immune response to co-delivered soluble antigens, (KLH, OVA, P. falciparum CelTOS, and 
soluble RSV), virus-like particles (norovirus), and inactivated viruses (dengue, influenza, and 
Sabin polio strains) [(286-290) and personal communication P. Jorquera, D. Tonkin, L. White, 
and R. Johnston]. More specifically, the immune responses observed using GVI3000 adjuvant 
included (1) enhanced antibody response, (2) balanced TH1/TH2 response, (3) antigen-specific T-
cell response, (4) mucosal IgA, IgG, and T-cell response and (5) protection. While most of the 
studies looking at the adjuvanticity of GVI3000 were performed in mice, some studies have been 
successfully performed in rats, ferrets, and non-human primates (R. Johnston, personal 
communication). 
 Another VEE based adjuvant is GVI3A, which contains a mutation in the GVI3000 
genome at the nt3 of the 5’ NTR. The nt3 mutation is a major attenuating mutation described in 
the TC-83 vaccine strain (271, 291) making it possible for the adjuvant production in BSL-2 
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conditions. While much remains to be understood, GVI3A adjuvant induced protective immune 
response in neonatally immunized mice challenged after a single immunization (unpublished 
observation).
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CHAPTER 2: A TETRAVALENT ALPHAVIRUS-VECTOR BASED DENGUE 
VACCINE PROVIDES EFFECTIVE IMMUNITY IN AN EARLY LIFE MOUSE 
MODEL# 
 
2.1. OVERVIEW 
Dengue viruses (DENV1-4) cause 390 million clinical infections every year, several hundred 
thousand of which progress to severe hemorrhagic and shock syndromes. Preexisting immunity 
resulting from a previous DENV infection is the major risk factor for severe dengue during 
secondary heterologous infections. During primary infections in infants, maternal antibodies 
pose an analogous risk. At the same time, maternal antibodies are likely to prevent induction of 
endogenous anti-DENV antibodies in response to current live, attenuated virus (LAV) vaccine 
candidates. Any effective early life dengue vaccine has to overcome maternal antibody 
interference (leading to ineffective vaccination) and poor induction of antibody responses 
(increasing the risk of severe dengue disease upon primary infection). In a previous study, we 
demonstrated that a non-propagating Venezuelan equine encephalitis virus replicon expression 
vector (VRP), expressing the ectodomain of DENV E protein (E85), overcomes maternal 
interference in a BALB/c mouse model. We report here that a single immunization with a 
tetravalent VRP vaccine induced NAb and T-cell responses to each serotype at a level equivalent 
to the monovalent vaccine components, suggesting that this vaccine modality can overcome 
                                                
#This chapter previously appeared as an article in the journal Vaccine. The original citation is as 
follows: Syed Muaz Khalil, Daniel R. Tonkin, Melissa D. Mattocks, Andrew T. Snead, Robert E. 
Johnston, Laura J. White. “A tetravalent alphavirus-vector based dengue vaccine provides 
effective immunity in an early life mouse model,” Vaccine, 2014 Jul 7;32(32):4068-74. 
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serotype interference.  Furthermore, neonatal immunization was durable and could be boosted 
later in life to further increase NAb and T-cell responses. Although the neonatal immune 
response was lower in magnitude than responses in adult BALB/c mice, we demonstrate that 
VRP vaccines generated protective immunity from a lethal challenge after a single neonatal 
immunization.  In summary, VRP vaccines expressing DENV antigens were immunogenic and 
protective in neonates, and hence are promising candidates for safe and effective vaccination in 
early life. 
 
2.2. INTRODUCTION 
The four serotypes of dengue virus (DENV) are the leading cause of the most important 
mosquito-borne viral disease worldwide, with annual estimates of approximately 390 million 
infections (151). The World Health Organization also estimates that up to half a million people 
are hospitalized with severe dengue disease (Dengue Hemorrhagic Fever/Dengue Shock 
Syndrome; DHF/DSS), and among them a large proportion are children (152). Children and 
adults are at increased risk of severe dengue upon a secondary infection with a different serotype. 
In addition, infants born to dengue immune mothers are at an increased risk of DHF/DSS during 
a primary infection, and account for more than 5% of all DHF cases (292, 293). This increased 
risk in infants seems to correlate with maternal antibody titers dropping to sub-neutralizing 
levels, and becoming potentially enhancing (292, 293). At present, there are no licensed dengue 
vaccines available, and the ones in development may not be effective in infants. 
In addition to the challenges inherent to immunizing early in life, when the immune 
system is suboptimal, additional unique challenges are encountered in the development of 
dengue vaccines. (A) A dengue vaccine must be tetravalent (TV) and induce equivalent and 
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durable neutralizing antibodies (NAbs) against all 4 serotypes simultaneously, due to the 
theoretical enhanced risk of severe disease if incomplete immunity is induced. (B) Serotype 
interference has been described among the components of some TV LAV vaccines in 
development. The dominant serotype prevents other serotype(s) from inducing adequate 
responses, resulting in incomplete immunity and the need for additional vaccinations over a one 
year period to achieve a tetravalent response (294). (C) In dengue endemic areas, most children 
are born with maternal antibodies (Abs) to DENV. These Abs protect in the first months, but also 
have the potential to interfere with and reduce the efficacy of LAV. Therefore, there is a need for 
early life vaccines that can induce balanced NAb responses after a single immunization given 
early in life, and that are not subject to maternal antibody interference. 
Venezuelan equine encephalitis virus replicon particles (VRP) are non-propagating viral 
vectors that can express high levels of an antigen protein after a single round of replication. 
VRP-based vaccines expressing various antigens induced protective immunity in rodent models 
(202, 203, 276-281), and in non-human primates (NHP) (283, 285). A VRP-based dengue 
vaccine candidate is immunogenic and protective in adult mice and NHP (156, 295). 
Furthermore, VRP expressing DENV2 prME was immunogenic in weanling mice even in the 
presence of maternal antibodies that prevented immunization with live virus (295). 
Here we hypothesize that the VRP vectors are well suited as an effective early life 
vaccine platform for dengue. First, VRP are propagation incompetent, and therefore safe. 
Second, VRP immunization is not dependent on vector propagation and amplification.  
Therefore, serotype interference is minimized as indicated by balanced responses to the 4 dengue 
serotypes in adult mice and non-human primates. Third, VRP induce strong Th1 immune 
responses, potentially overcoming one of the deficiencies in the neonatal immune response. And 
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finally, since VRP contain no DENV antigens, maternal antibodies are less likely to interfere 
with the vaccine, as was demonstrated previously (295). 
 
2.3. MATERIALS & METHODS 
Cells and Viruses 
Vero81, BHK-21, and C6/36 cells were obtained from the American Type Culture 
Collection (ATCC) and appropriately maintained as described previously (156). WHO reference 
DENV strains were used in the neutralization assays: DENV1 WP, DENV2 S-16803, DENV3 
CH53489, and DENV4 TVP-360 (provided by R. Putnak from WRAIR). The viruses were 
propagated no more than three times in C6/36 cells, titrated on Vero cells, and stored at -80°C. 
The mouse-adapted, neurovirulent New Guinea C (NGC) strain of DENV2 used for challenge 
studies (provided by the late Robert Shope, UTMB, Galveston, TX) was amplified no more than 
twice in C6/36 cells and stored at -80°C at a concentration of 1×107PFU/ml.  
 
DV1-4 VRP Vaccines 
The construction and production of VRP vectors expressing a C-terminal truncated 
protein representing 85% of the E protein (E85) from DENV1-4 as well as their source have 
been described in detail elsewhere (156). 
 
Mice and immunizations 
Pregnant and adult BALB/c mice were purchased from Charles River and were housed at 
the Global Vaccines Inc. or at the University of North Carolina. The animals were housed and 
cared for in accordance with the protocols approved by each facility’s Institutional Animal Care 
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and Use Committees. Pregnant mice were closely observed for date and approximate time of 
delivery. Adult mice (6-8 weeks old) or neonatal mice (7 days old) were anesthetized (only 
adults) and injected in both rear footpads with vaccine or diluent (5µl in each rear footpad.  
 
Neutralization assay 
Neutralizing antibody titers specific for DENV1-4 were quantified using a flow 
cytometry-based neutralization assay on Vero cells, as previously described (156). MAb 2H2 
(binds prM protein) was used for intracellular staining of dengue-infected cells.  
 
Surface and intracellular staining (ICS) 
Mouse spleens were harvested, homogenized, and strained through 40µm cell strainers to 
get single cell suspensions. The CD8/CD4 T cell responses were elicited after splenocytes were 
cultured in RPMI-10 media containing brefeldin A (GolgiPlug, BD Biosciences) with the 
appropriate peptide pool (2 µg/ml) (see figure legends for detail) for 18 h at 37°C. Cells were 
stained for CD8 and CD4 (eBioscience) in PBS at 4°C, fixed and permeabilized in 
Cytofix/Cytoperm (BD). For ICS, fixed cells were stained with antibody specific for IFN-γ  
(eBioscience). Cells were analyzed on an Accuri™ C6 Flow Cytometer (BD). The final results 
were obtained after normalizing the value in each sample by subtracting the value obtained in 
mock-stimulated cells. Spleens harvested from GFP-VRP immunized mice were also included as 
control. 
 
IFN-γ  enzyme-linked immunospot (ELISPOT) assay 
An IFN-γ ELISPOT assay was performed to measure DENV3 E-specific IFN-γ-secreting 
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cells in the popliteal draining lymph nodes of neonatally immunized mice. Mouse IFN-γ capture 
antibody (R&D Systems) was incubated on nitrocellulose membrane plates (96 well; Millipore) 
overnight at 4°C. Single cell suspensions in RPMI-10 (2.5×105 cells per well) from popliteal 
DLN were added after washing the plates. Peptides (see figure legends for detail) were added at 
final concentration of 2 µg/ml for 36 h. IFN-γ spots were developed according to manufacturer’s 
protocol (R&D Systems) and the plates scanned by Cellular Technologies Ltd. [Shaker Heights, 
OH].  
 
Challenge 
Survival after DENV challenge was studied in mice three weeks after MV and TV 
neonatal immunization. Immunized and PBS control mice were anesthetized and challenged by 
intracranial injection with 5×104 PFU of mouse-adapted strain DENV2 NGC virus. Mice were 
observed for 25 days for weight change, morbidity, and mortality. Mice were euthanized if their 
weight dropped below 80% of their initial weight. 
 
Statistical analysis 
Neutralization titers and immune cell values were evaluated for statistically significant 
differences by either the ANOVA or Mann–Whitney tests (GraphPad Prism). Statistical 
significance is reported as follows (*, p < 0.05; **, p < 0.01; ***, p < 0.001). 
 
2.4. RESULTS 
VRP expressing monovalent dengue E85 protein induces a sustained neutralizing antibody 
response after a single immunization 
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The kinetics of the Nab response after one immunization with DENV3 E85-VRP was 
compared in adult and neonatal mice. Adult and neonatal mice were given a single immunization 
with 1×106 IU of DV3-VRP. Mice were bled at 3, 6, and 13 (15 in neonates) weeks post 
immunization (wpi) (Figures 2.1A & 2.1B). A single immunization in both adult and neonatal 
mice induced a NAb response in all animals. In neonates, the NAb titers against DENV3 
remained below the limit of detection at 3 wpi, increased and peaked at around 6 wpi and 
remained relatively stable for up to 15 wpi (last time-point tested). While induction of NAbs in 
adult mice showed similar kinetics, titers were significantly higher than those in neonates. A 
VRP vaccine expressing E85 from a serotype 2 (DV2-VRP) yielded serotype-specific NAbs in 
neonates with similar kinetics to DV3-VRP (data not shown).  
 
Neutralizing antibody titers induced by monovalent (MV) and tetravalent (TV) vaccination 
To determine whether each serotype VRP vaccine was immunogenic, and whether there 
was serotype interference among the 4 components in the TV formulation, adult and neonatal 
mice were immunized with each MV component separately or in the TV mix, and NAbs were 
measured. In adult mice, two immunizations with TV-VRP induced comparable NAb titers to 
each dengue serotype (Figure 2.2A-D). In addition, the NAb titers induced by each serotype 
when administered as MV vs. TV vaccine were similar (p>0.2). In neonates, a single 
immunization with TV vaccine induced NAbs to all 4 serotypes in every animal. Like in adult 
mice, NAb titers for serotypes 1, 2, and 3 (serotype 4 was lost to analysis) were not significantly 
different between the TV and MV formulations, (Figure 2.2E-H), suggesting that serotype 
interference was minimized when using the VRP vaccine approach. 
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VRP induces T cell responses to DENV3 E protein in mice immunized with monovalent or 
tetravalent vaccine 
To determine whether DENV envelope-specific T-cells are induced upon VRP 
immunization, adult mice were immunized with either 106 IU of DV3-VRP or a TV formulation 
with 106 IU each of the four serotypes. All mice were boosted with the homologous vaccine 
before harvesting spleens 8 days post-boost for ICS. In cells stimulated with a pool of DV3 E 
peptides, we observed IFNγ+ CD8+ T-cell responses against DENV3 envelope for both MV and 
TV immunizations, and these did not differ significantly, p=0.49 (Figure 2.3A). Furthermore, 
DENV3 E-specific IFNγ+ CD4+ T cells were induced and were not significantly different 
between MV and TV vaccines (p=0.07). In a separate experiment, a similar result was observed 
(data not shown). 
Neonatal mice received a single immunization with 106 IU DV3-VRP (Figure 2.3B). 
DLN and spleens were harvested on 8 dpi. Due to the limited number of immune cells present in 
neonatal DLN, an IFNγ-ELISPOT assay was performed instead of ICS. We observed that both 
MV and TV immunizations induced similar levels of IFNγ-secreting cells in the neonatal DLN 
(p=0.93). Antigen-specific IFNγ-secreting cell numbers in the spleen were reduced; however, 
they were not significantly different for MV and TV immunized mice (p=0.94). Since the 
harvested immune cells were stimulated with a panel of pooled DENV3 envelope peptides, we 
infer that most, if not all, of the IFNγ secreting cells were antigen-specific T-cells. 
 
Neonatal priming with VRP improves immune responses upon a later adult immunization 
Three groups of mice were immunized on d7 post-birth, on d7 & d35, or only on d35. All 
mice received 106 IU DV3-VRP (Figure 2.4A). On d56, serum was collected for neutralization 
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assays. Significantly higher Neut50 titers were observed in mice that had been primed as neonates 
and boosted as adults (GMT = 601) compared to immunization on d7 only (GMT = 95; p <0.05) 
The increase after the booster immunization was mostly due to the prime, mice immunized on 
d35 only had reduced NAb titers (GMT = 121; p=0.0519). A parallel experiment with DV2-VRP 
was set up to investigate the CD8 T-cell responses, in which the spleens were harvested on day 
43. Using ICS, single cell suspensions of splenocytes were evaluated for the presence of IFNγ-
secreting CD8 T-cells following stimulation with a panel of pooled DENV2 E-protein peptides. 
As seen for the NAb response, there was a significantly higher T-cell response in mice receiving 
two immunizations compared to those that only received immunization on d35 only or day 7 
only (Figure 2.4B). 
 
A single neonatal immunization with the VRP-based vaccine confers protection from 
dengue challenge 
Protection was determined using an intracranial DENV2 challenge model. Neonatal mice 
immunized with TV-VRP, DV2-VRP or PBS were challenged 3 weeks later with a mouse brain-
adapted DENV2 strain. While all the PBS immunized mice succumbed to challenge by day 17, 
mice receiving either the MV DV2-VRP or the TV vaccine had significantly better protection 
with 5/6 (p=0.0024) and 4/6 (p=0.0018) mice surviving the challenge, respectively (Figure 2.5). 
There was no significant difference between the MV and TV immunized groups. In a separate 
experiment, weanling BALB/c mice (21 days old) vaccinated with 106 IU DV2-VRP were 
protected (8 out of 9 animals) from a lethal challenge at three weeks post-immunization. The 
control mice immunized with 106 IU HA-VRP (expressing an irrelevant influenza HA antigen) 
did not confer any protection (0/8) (supplementary figure 2.1). 
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2.5. DISCUSSION 
There is currently no licensed vaccine for dengue, and the vaccine candidates in advanced 
clinical trials do not target children <12-15 months of age. Developing a dengue vaccine that can 
be administered during the first year of life is important for 2 reasons. First, in dengue endemic 
areas, most children are born with dengue maternal antibodies, which are protective during the 
first few months of life.  However, these maternal antibodies become a risk factor for severe 
disease via ADE when they wane to sub-neutralizing titers (292, 293). An early life vaccine 
would protect these infants at risk of DHF/DSS. Second, vaccinating early in life in endemic 
regions would have the advantage of vaccinating a population more likely to be uniformly 
DENV-naïve, avoiding having to vaccinate older subjects with differences in pre-existing 
immunity, which may affect vaccine-induced immunity in unknown ways.  
 Our study is the first to address the challenges of immunizing against dengue early in life, 
and to demonstrate that the VRP vaccine platform is an effective early life dengue vaccine 
candidate. The present study demonstrates that VRP vaccines can induce NAbs in neonatal mice 
after a single immunization and that the titers remain stable until at least 15wpi. Although these 
titers were reduced at all time-points post-immunization compared to those in adult mice, this 
finding was not surprising, as the neonatal immune response is known to be weaker (68, 70, 101, 
296), resulting in lower serum antibody titers (36, 297) of shorter duration (298, 299). 
Dengue vaccines in development seek to induce robust NAbs to all 4 serotypes (300). 
However, results from the first dengue phase IIb efficacy trial suggest that cell-mediated 
immunity may be needed in a dengue vaccine (301), and a recent study suggests that the DENV-
specific CD8+ T-cell response in humans correlates with protection in an HLA-specific manner 
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(302). VRP vaccines induce robust CD8+ CTL responses in adult mice to other antigens (303). 
Even though neonates induce significantly reduced CTL responses (70), our studies showed 
dengue-specific IFNγ-secreting cells in the DLN of neonatal mice, which we infer to be 
predominantly CD8+ (Figure 2.3B). This is based on observations in adult mice, which showed 
an approximately 10-fold higher quantity of dengue-reactive CD8+ cells compared to CD4+ 
cells (Figure 2.3A). Direct comparison between neonates and adults in the current study is 
difficult, because there was only a single neonatal immunization, while adult mice were 
immunized twice. However, this is the first study to our knowledge that shows induction of a 
DENV-specific T-cell response in neonatal mice after a single immunization. We predict that 
addition to the immunization cocktail of VRP expressing DENV NS3 and/or NS5, major targets 
of T-cell responses, will result in a stronger antigen-specific CD8+ T-cell response. 
 The induction of equivalent NAb responses has been a major challenge for vaccines 
based on replicating antigens, where different rates of replication or immunodominance result in 
unbalanced responses (294, 304).  In a TV, non-propagating VRP vaccine, the 4 components 
presumably have similar replication rates, reducing the chances of serotype interference. Indeed, 
we show here a VRP-based TV vaccine induced equivalent titers to each serotype after a single 
dose in neonates, and the NAbs induced were comparable to those induced by each individual 
component when tested as a MV vaccine. 
It is possible that the serotype-specific NAbs measured 3 weeks after TV vaccination 
could be attributed to cross-reactive NAbs induced by the dominant serotypes. This is unlikely 
for two reasons. First, studies in adult mice indicate that MV E85-VRP vaccines predominantly 
induce homologous NAbs with very low amounts of cross-reactive NAbs (data not shown). 
Second, since cross-reactive NAbs induced by one serotype are short-lived (305, 306), 
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measuring NAbs to all 4 serotypes long after immunization reflects a true TV response. This was 
indeed demonstrated 73-weeks after immunization of adult mice with two doses of TV VRP 
vaccine expressing DENV1-4 prME (supplementary figure 2.2). 
A previous study demonstrated that a DENV-VRP vaccine was not subject to otherwise 
interfering maternal antibodies when it was used to immunize weanling mice born to DENV-
immune dams (295). Maternal antibody interference is one of the most important obstacles to 
developing an early life dengue vaccine, especially because LAV are likely to be ineffective at 
this age due to maternal antibodies interfering with the replication of the vaccine strains. 
 Reducing the risk of DHF in early life after a single immunization will allow 
opportunities for a second immunization to further improve the immune response. Anti-vector 
immunity is undetectable-to-low after a single VRP immunization in NHP, and does not prevent 
a second VRP immunization from having a booster effect on dengue-specific NAbs (156). This 
suggested that infants primed with a VRP vaccine could be safely and effectively boosted with a 
second dose of a VRP vaccine. Neonatal mice primed on d7 appear to produce more NAb after a 
boost on d35 than animals that received a single inoculation on d35 (p=0.0519).  Similarly, the 
CD8+ T-cell response is significantly higher when the mice were first primed as neonates 
(p=0.0498).  Although these p-values hover around the limit of significance, we feel that 
immunizing neonatal animals not only will have a salutary effect on protection of neonates as 
maternal NAb wanes, but also will prime an improved boost response going forward. The second 
immunization as an adult could utilize a homologous or heterologous vaccine platform to 
broaden and strengthen the immune response. Although anti-vector immunity is a concern that 
remains to be addressed in humans, studies in adult mice (unpublished data) and macaques (156), 
have shown anti-VEE NAbs do not have any significant effect on the induction of NAbs to 
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vaccine antigens. Another potential concern is the chance of in vivo recombination if vaccination 
occurs at the same time as infection with wild type virus. This event is highly unlikely to result 
in recombinant virus of more virulence than the wild-type infecting virus itself. 
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Figure 2.1 
 
Figure 2.1. DENV3-VRP vaccine induces neutralizing antibody response after a single 
immunization in neonates and adult mice. 
Adult mice were anesthetized before immunization by intraperitoneal (i.p.) injection with a 4/1 
mixture (vol/vol) of ketamine (50 µg/g body weight) and xylazine (15 µg/g body weight). (A) 
Six adult BALB/c mice (6 weeks old) were immunized with 1×106 IU of monovalent DV3 -VRP 
and neutralizing antibody titers were measured in the sera at 3, 6, and 13 weeks post-
immunization. (B) Six neonatal mice were immunized on day 7 after birth with 1×106 IU of 
monovalent DV3 -VRP. Three, 6, and 15 weeks after the immunization, neutralization antibody 
titers were measured in the sera of the immunized mice. Note: There were only five samples for 
6 weeks time-point. Data are presented as 50% neutralization titers (Neut50) (GMT +/- 95% CI). 
The limit of detection for this assay was 10. 
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Figure 2.2 
 
Figure 2.2: Serotype-specific Nab titers induced by each MV and TV vaccine in adult and 
neonatal mice. (A-D)  
Eight adult BALB/c mice per group were immunized and boosted (under anesthesia) 4 weeks 
later with 2×106 IU of each monovalent vaccine, DV1-VRP, DV2-VRP, DV3-VRP, or DV4-
VRP or with a tetravalent cocktail of the above four VRP vaccines at 106 IU each. NAbs were 
determined at 3 weeks post boost. Graphs A-D represent Neut50 titers against serotypes 1-4 
respectively. Each graph includes NAbs induced by the monovalent (white bars) or the 
tetravalent (black bars) vaccine. Data are presented as GMT +/- 95% CI. The limit of detection 
for this assay was 10. (p values: DENV1 = 0.59; DENV2 = 0.24; DENV3 = 0.24; DENV4 = 
0.26). (E-H) Neonatal mice were immunized on day 7 after birth with 1×106 IU of either 
monovalent DV1-VRP (N=7), DV2-VRP (N=9) or DV3-VRP (N=6). A tetravalent 
immunization with 1×106 IU of each DV1-, DV2, DV3, and DV4-VRP expression vectors were 
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administered to a group of 6 neonatal mice. Neut50 titers were determined at 15 weeks post 
immunization. (p values: DENV1 = 0.95; DENV2 = 0.52; DENV3 = 0.01). Monovalent DV4-
VRP immunization data was lost to analysis (Figure 2H). 
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Figure 2.3 
 
Figure 2.3: Induction of DENV E-specific cell-mediated immunity (CMI) after monovalent 
and tetravalent VRP immunization in adult and neonatal mice.  
(A) CD4+ and CD8+ T cell responses in adult mice. Adult BALB/c mice (4 per group) were 
immunized and boosted (under anesthesia) 4 weeks later with 106 IU of either monovalent DV3-
VRP or a tetravalent cocktail of 106 IU each of DV1-VRP, DV2-VRP, DV3-VRP, and DV4-
VRP (TV-VRP). Splenocytes were obtained 8 days after booster immunization and stimulated 
with peptide in vitro. Overlapping peptides derived from DENV3 E protein were used (68 
DENV3 E peptides, BEI NR-9228), which were resuspended in DMSO and pooled. Cells were 
stained by ICS for IFNγ after surface staining of CD4 and CD8. Data were normalized to mock-
stimulated splenocytes of each individual mouse. (B) CMI after a single immunization in 
neonatal mice. Six neonatal mice per group (five in tetravalent DLN group) were immunized 
with 106 IU of either monovalent DV3-VRP or a tetravalent cocktail of 106 IU each of DV1-
VRP, DV2-VRP, DV3-VRP, and DV4-VRP (TV-VRP). At 8 days post immunization spleens 
and DLN were harvested. The two popliteal DLNs from each mouse were combined. For 
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immune cell stimulation, 68 DENV3 E peptides obtained from BEI (NR-9228) were individually 
resuspended in DMSO, and pooled in three panels: A (peptides 1 to 23), B (peptides 24 to 46), 
and C (peptides 47 to 68). Unpublished observations in adult mice showed the highest immune 
response to E was in peptide pool B (includes amino acid sequence from 174 to 343), DLN 
immune cells were stimulated with E peptide pool B. IFNγ-producing cells were quantified by 
ELISPOT assay. Data were normalized to mock-stimulated DLN cells of each individual mouse. 
All results were graphed as mean +/- SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 54 
Figure 2.4 
 
 
Figure 2.4: Neonatal immunization with VRP vaccine primes robust neutralizing antibody 
and T-cell responses.  
(A) Neutralizing antibody responses – Three groups of mice were immunized with 106 IU of 
DV3-VRP as follows: on day 7 after birth, groups 1 (n=6, white bars) and group 2 (n=6, black 
bars) received VRP vaccine, and group 3 (n=5, gray bars) received diluent (PBS + 0.1%HSA). 
On day 35, groups 2 and 3 received VRP vaccine, and group 1 received diluent (all under 
anesthesia). On day 56, all groups were bled and Neut50 titers vs. DENV2 were determined. 
Bars represent GMT +/- 95% CI. (B) T-cell responses – Three groups of mice were immunized 
with 106 IU of DV2-VRP as described in figure 4A. Groups 1 and 2 had 3 mice each and group 3 
had 4 mice. On day 43 (8 days post boost) splenocytes from all mice were harvested followed by 
stimulation with DENV2 E-protein peptide cocktail (67 peptides, BEI NR-507), surface staining 
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for CD8, and intracellular cytokine staining for IFNγ. Data were normalized to mock-stimulated 
splenocytes of each individual mouse, and expressed as number of CD8+ T cells per 106 cells. 
Results were graphed as mean +/- SEM. * indicates p<0.05. 
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Figure 2.5 
 
Figure 2.5: VRP expression vector immunization is protective in mice after a single 
immunization on day 7.  
Six 7-day-old neonatal BALB/c mice were immunized with 106 IU of either monovalent DV2-
VRP or a tetravalent cocktail of 106 IU each of DV1-VRP, DV2-VRP, DV3-VRP, and DV4-
VRP (TV-VRP). Six control neonatal mice were immunized with diluent. Three weeks after 
immunization, all mice were challenged intracranially (under anesthesia) with 5×104 PFU of a 
mouse-adapted, neurovirulent New Guinea C strain of dengue virus serotype 2. The mice were 
observed daily for 25 days after challenge. Results are presented as percent survival. 
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Supplementary Figure 2.1 
 
Supplementary Figure 2.1: Monovalent DV2-VRP immunization is protective in mice after 
a single immunization on day 21.  
Nine 21-day-old weanling BALB/c mice were immunized with 106 IU of monovalent DV2-VRP. 
Eight control weanling mice were immunized with VRP expressing influenza hemagglutinin 
(VRP-HA). Three weeks after immunization, all mice were challenged intracranially (under 
anesthesia) with 1×104 PFU of a mouse-adapted, neurovirulent New Guinea C strain of dengue 
virus serotype 2. The mice were observed daily for 20 days after challenge. Results are presented 
as percent survival. 
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Supplementary Figure 2.2 
 
Supplementary Figure 2.2: TV-prME-VRP vaccine induces long-term neutralizing 
antibody response to each component of the vaccine in adult mice.  
All mice were anesthetized before immunization by intraperitoneal (i.p.) injection with a 4/1 
mixture (vol/vol) of ketamine (50 µg/g body weight) and xylazine (15 µg/g body weight). Eight 
adult BALB/c mice (6 weeks old) were immunized (prime) with 1.8×105 IU of each VRP 
expressing the full-length prME cassette (DV1-, DV2-, DV3-, and DV4-prME-VRP) in a 
cocktail and boosted at 8 weeks post-prime with a cocktail containing 2×105 IU of each prME-
VRP. Neutralizing antibody titers were measured in the sera at 0, 4, 8, 11, 16, 22, 31, and 79 
weeks post-prime immunization. Sera from week 0 (pre-immunization) are assigned a value of 
1:10, which is one dilution below the limit of detection (LOD) of this assay (1:20). Dotted line 
represents the LOD. Data are presented as 50% neutralization titers (Neut50) (GMT +/- 95% CI).
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CHAPTER 3: AN ALPHAVIRUS-BASED ADJUVANT ENHANCES SERUM AND 
MUCOSAL ANTIBODIES, T CELLS AND PROTECTIVE IMMUNITY TO 
INFLUENZA VIRUS IN NEONATAL MICE∗ 
 
3.1. OVERVIEW   
Neonatal immune responses to infection and vaccination are biased towards TH2 at the 
cost of pro-inflammatory TH1 responses needed to combat intracellular pathogens.  However, 
upon appropriate stimulation, the neonatal immune system can induce adult-like TH1 responses. 
Here we report that a new class of vaccine adjuvant is especially well suited to enhance early life 
immunity.  The GVI3000 adjuvant is a safe, non-propagating, truncated derivative of 
Venezuelan equine encephalitis virus that targets dendritic cells (DC) in the draining lymph node 
(DLN) and produces intracellular viral RNA without propagating to other cells. RNA synthesis 
strongly activates the innate immune response so that in adult animals, co-delivery of soluble 
protein antigens induces robust humoral, cellular and mucosal responses. The adjuvant properties 
of GVI3000 were tested in a neonatal BALB/c mouse model using inactivated influenza virus 
antigen (iFlu). After a single immunization, mice immunized with GVI3000-adjuvanted iFlu had 
significantly higher and sustained Flu-specific IgG antibodies, mainly IgG2a (TH1), compared to 
the antigen-only group. GVI3000 significantly increased antigen-specific CD4+ and CD8+ T-
cells, primed mucosal immune responses, and enhanced protection from lethal challenge. As 
                                                
∗ This chapter previously appeared as an article in the The Journal of Virology. The original 
citation is as follows: Syed Muaz Khalil, Daniel R. Tonkin, Andrew T. Snead, Griffith D. Parks, 
Robert E. Johnston, Laura J. White. “An Alphavirus-based Adjuvant Enhances Serum and 
Mucosal Antibodies, T cells and Protective Immunity to Influenza Virus in Neonatal Mice,” The 
Journal of Virology, 2014 Jun 4 pii: JVI.00327-14. [Epub ahead of print]. 
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seen in adult mice, the GVI3000 adjuvant increased the DC population in the DLN, caused 
activation and maturation of DC, and induced proinflammatory cytokines and chemokines in the 
DLN soon after immunization, including IFN-gamma, TNF-alpha, G-CSF and IL-6. In summary, 
the GVI3000 adjuvant induced an adult-like adjuvant effect with an influenza vaccine, and has 
the potential to improve the immunogenicity and protective efficacy of new and existing 
neonatal vaccines. 
 
3.2. INTRODUCTION 
 The World Health Organization (WHO) estimates approximately 2 million deaths in 
neonatal and infant humans (<1 year of age) every year worldwide due to acute infections caused 
by a limited number of pathogens (157). The availability of effective early life vaccines against 
those agents would have a significant impact on disease burden in neonates and infants, who are 
especially vulnerable to infectious diseases, and in whom the immune responses generated by 
most currently available early life vaccines are suboptimal. The need for effective early life 
vaccines is especially important in resource-poor countries, where the period immediately after 
childbirth is often the only point of contact with the healthcare system. 
 A major obstacle in the development of early life vaccines is that the neonatal immune 
system is geared more towards a TH2 response at the cost of more pro-inflammatory TH1 
responses needed to combat intracellular pathogens (68, 307). The neonatal antibody response to 
conventional subunit and live attenuated vaccine antigens is of limited magnitude and duration 
and CD8+ T cell responses also are reduced compared to adults (70, 134, 308). The 
predisposition of the neonatal immune system towards a TH2 response is caused by the 
suboptimal innate immune response, with delayed maturation of neonatal dendritic cells (DCs) 
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and limited production of inflammatory cytokines, which leads to inefficient antigen presentation 
and stimulation of naïve T-cells (65, 309-311). Therefore, many vaccines that are effective in 
adults are poorly immunogenic in early life, hence requiring multiple booster immunizations 
(70). 
 Influenza viruses cause millions of annual infections worldwide, with up to 40,000 deaths 
reported in the U.S. alone (141). Newborns and infants are at higher risk for influenza-related 
mortality because of their immature immune systems, which can often lead to severe viral 
pneumonitis or bacterial super-infection (312). Protection from influenza, like most respiratory 
viruses, is optimally conferred through virus-specific antibodies, such as IgG and IgA. However, 
antibody-mediated protection does not fully protect against heterologous strain infection due to 
the variability in the surface glycoproteins (313). On the other hand, T-cell epitopes are highly 
conserved across influenza strains and robust T-cell response can induce a broader protection 
(314). Currently available influenza vaccines—tetravalent inactivated (TIV) or live attenuated 
(LAIV)—are not recommended for use in infants <6 months (146). While the LAIV 
immunization has been more effective in young children (6-11 months) compared to TIV, it has 
been associated with safety concerns, such as increased rate of wheezing and hospitalization 
(149, 150). Therefore, the development of inactivated influenza vaccines, with improved efficacy 
in infants less than 6 months of age is urgently needed. In this study, we chose inactivated 
influenza virus as a model antigen. 
Studies have shown that upon appropriate stimulation, the otherwise “immature” neonatal 
immune system has the capacity to induce adult-like TH1 immune responses, and protect against 
infections (68). The best example of a neonatal TH1 vaccine is the Bacille Calmette Guerin 
(BCG) vaccine against tuberculosis, which induces strong, adult-like IFNγ responses and a 
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protective TH1 response in newborns. The WHO has recommended BCG for immunization 
immediately after birth (315). An increased interest in developing and testing TH1-inducing 
adjuvants for early life immunizations has resulted in a number of studies in human cord blood 
cells and in neonatal animal models, using cytokines and ligands of Toll-like receptors (TLR). 
Stimulation of CD4+ T-cells from human umbilical cord blood with recombinant IL-12 resulted 
in the induction of adult-like IFNγ responses (316). TLR7/8 agonists, R848, or TLR8 agonist 
VTX-294 showed TH1-responses, indicated by production of cytokines TNFα, IL-1β, and IL-12 
secreted by APCs from newborn cord blood (317, 318). CpG, aTLR9 agonist, can induce adult-
like DC and T cell activation, while failing to induce adult-like Ab responses (109). IC31 
(Intercell AG), a two-component adjuvant consisting of an antibacterial peptide and the TLR9 
agonist ODN1a, when combined with a Pneumococcal conjugate vaccine, enhances protective 
immunity in neonatal mice (319). A synthetic water-in-oil emulsion based adjuvant, CRL-8941 
(116), and Complete Freund’s Adjuvant, CFA (72), induced adult-like TH1 immune responses in 
neonatal mice, indicated by induction of antigen-specific IgG2a antibodies (an indicator of a TH1 
response in BALB/c mice) and/or IFNγ-secreting splenocytes. However, CRL-8941 was reported 
by the authors to cause “significant local toxicity” in neonatal mice while CFA is universally 
toxic. Therefore, there is a continued need for safe and effective adjuvants that can promote 
strong, balanced and protective newborn immune responses to new and existing vaccines. The 
two adjuvants currently approved as components of human vaccines, alum and MF59, are both 
inducers of TH2 polarized immune responses (320). Therefore, an adjuvant promoting a TH1 
response might be useful in inducing a balanced vaccine response by the already TH2 biased 
neonatal immune system.   
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 In this study, we investigated the effectiveness of a new class of adjuvants in early life 
vaccination. The novel adjuvant GVI3000 is derived from an alphavirus genome. Venezuelan 
equine encephalitis virus (VEE) is a positive-sense, single stranded RNA virus representative of 
the alphavirus genus. Its ~11.5 Kb RNA genome encodes four non-structural proteins and 3 
structural proteins, the latter expressed from a 26S subgenomic promoter. Although the adjuvant 
properties of attenuated VEE virus have been suggested for some time (321, 322), our group has 
developed and characterized propagation incompetent VEE replicon particles with strong 
adjuvant activity (286), and analogous adjuvants have been derived from Semliki Forest virus 
(323) and Sindbis (Mikkelsen and Johnston, unpublished). VEE adjuvant particles have been 
referred to as nVRP (286, 287) or GVI3000 (290), and contain a truncated VEE genome that 
includes the 5’ and 3’ UTRs and the nonstructural genes, but lack the 26S subgenomic promoter 
and the structural protein genes. When inoculated into adult mice by subcutaneous, intradermal 
or intramuscular routes with a number of soluble (OVA, KLH) or inactivated particulate antigens 
(noro-, polio-, or influenza viruses), these adjuvant particles can enhance humoral, cellular, and 
mucosal immune responses (286, 287, 289, 290). Additionally, enhanced protection against 
influenza and dengue viruses was demonstrated in a macaque model (156, 324). Upon 
subcutaneous immunization of mice, GVI3000 particles enter Langerhans cells (LC) at the site of 
inoculation where viral RNA replication and LC activation presumably occurs (198). These 
infected immune cells then rapidly migrate to the draining lymphoid node(s) (DLN). 
Alternatively, GVI3000 particles can migrate directly to DLN, where they preferentially target 
DCs (198, 325). In both human- and murine-derived DCs, in vitro studies have shown an 
upregulation of co-stimulatory molecules as well as secretion of proinflammatory cytokines, 
such as type I IFN, IL-6, and TNF after infection (303, 325, 326). In adult mice, cytokine 
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secretion was observed systemically and in the DLN as soon as 6 hours after GVI3000 
inoculation (unpublished observation). Tonkin et al (268) demonstrated that DCs infected ex vivo 
with GVI3000, when inoculated into adult BALB/c mice, were sufficient to enhance in vivo 
systemic, mucosal, and cellular responses. Furthermore, the immune cells most frequently 
targeted and recruited to the draining lymph node were monocyte-derived inflammatory DCs. 
 Based on the properties of the GVI3000 adjuvant, we predicted that it might be well 
suited as a TH1-polarizing vaccine adjuvant to enhance neonatal immunization. We hypothesize 
that GVI3000 can induce a sufficiently strong DC activation to overcome the neonatal limitation 
to induce a Th1 response, hence promoting an “adult-like immune response,” shifting the 
neonatal immune system to a more balanced TH1- TH2 response, inducing mucosal and T cell 
responses, and improving vaccine efficacy in neonates.  
In this study we used a 7-day old BALB/c neonatal mouse model, which has been 
reported to more closely resemble the stage of immune maturation and immune-function 
limitations in human neonates (70). We immunized 7-day old and adult mice with inactivated 
influenza virions (iFlu) in the presence of GVI3000 adjuvant and compared the effect of the 
adjuvant on induced adaptive and innate immune responses after a single immunization of the 
two age groups. Antigen-specific antibody responses were significantly enhanced by the 
adjuvant and lasted for at least several months. GVI3000-adjuvanted iFlu also was able to induce 
antigen-specific T-cells in the DLN of immunized neonates, and primed a mucosal IgA response. 
The addition of the GVI3000 adjuvant to the iFlu vaccine resulted in a significant increase in 
protection from a lethal challenge. Furthermore, as observed in adults, inflammatory DCs were 
the most frequently recruited and targeted immune cells in the DLN. The pro-inflammatory 
innate immune response profile was similar to that in adult immunized mice, indicating that 
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GVI3000 exploits similar pathways in both neonates and adults and can overcome any 
shortcomings in the neonatal immune system. These findings support the conclusion that co-
delivery of GVI3000 and an inactivated vaccine can significantly improve immune responses 
and protection against challenge in neonatal mice.  
 
3.3. MATERIALS & METHODS 
Cells 
Vero81 cells were obtained from the American Type Culture Collection (ATCC). The 
Vero81 cells were maintained at 37°C in Dulbecco’s modified Eagle’s medium (DMEM)/F12 
medium supplemented with 10% fetal calf serum, penicillin/streptomycin (100 U/ml), and 
streptomycin (100 µg/ml) in the presence of 5% CO2. L929 mouse fibroblast cells (ATCC CCL-
1) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum, penicillin/streptomycin (100 U/ml), and 0.29 mg/ml of L-glutamine. Chicken 
red blood cells (CRBCs) were obtained from Charles River Laboratories (Material No. 
10100767), stored at 4°C for hemagglutination inhibition assays. 
 
Viruses and vaccine antigens 
Live Influenza A/PR/8/34 virus (Material No. 10100374) and formalin-inactivated 
Influenza virus A/PR/8/34 (iFlu) (Material No. 10100782) were obtained from Charles River 
Laboratories and stored at -80°C until use. 
 
Adjuvant VEE Replicon Particles (GVI3000) 
The production of GVI3000 adjuvant particles, also known as nVRP, has been described 
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previously (201, 204, 287). Briefly, in vitro transcribed VEE replicon RNA genome, together 
with two helper RNAs—expressing viral structural genes in trans—were co-electroporated into 
Vero81 cells. GVI3000 particles were collected in the culture media 24 h after electroporation. 
These particles contain only replicon RNA and exclude helper RNAs, which lack the viral-
specific packaging signal, rendering these particles propagation incompetent. Cytopathic effect 
testing was performed on each production batch to confirm the absence of detectable 
propagation-competent virus that could arise as a contaminant due to RNA recombination. The 
adjuvant particles were concentrated by ultracentrifugation through a 20% sucrose cushion, 
suspended in PBS containing 1% human serum albumin, and stored at -80°C until use. GVI3000 
infectious particles were then titered by infection of Vero cells as measured by 
immunofluorescent staining of VEE non-structural proteins, using polyclonal sera from mice 
immunized with VEE non-structural protein 2. 
Two modalities of VEE replicon RNA were packaged in this study:  (i) GVI3000 
replicon RNA, which encodes the 5’ and 3’ untranslated regions (UTR) flanking the viral 
nonstructural genes, but lacks the sequence between the nsP4 stop codon (5 nts before the 26S 
mRNA transcription start site) and the beginning of the 118-nt 3’ UTR (287). (ii) GVI3000-GFP 
replicon RNA, which encodes the viral nonstructural protein genes and also the sequence for 
GFP under the control of the viral 26S subgenomic promoter. GVI3000-GFP was used as 
reporter particles to identify GVI3000-infected cells. All known cis-acting signals for RNA 
replication were included in the GVI3000 genomes. All replicon particles were packaged using 
wild-type VEE (V3000) envelope sequences (274). 
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Mice and immunizations 
Pregnant and adult BALB/c mice were purchased from Charles River and were housed at 
the Global Vaccines Inc. animal facility.  All studies were carried out in accordance with the 
recommendations of the Guide for the Care and Use of Laboratory Animals. All animal 
protocols were approved by the Global Vaccines, Inc. Institutional Animal Care and Use 
Committees (IACUC) prior to their performance. Pregnant mice were closely monitored for date 
and approximate time of delivery.  
Seven days after birth, neonatal mice were injected in both rear footpads with PBS or one of the 
following formulations: iFlu alone, iFlu mixed with alum (Alhydrogel 2%; Invivogen) or iFlu 
mixed with GVI3000. The immunization volume was 10µl total (5µl in each rear footpad). Mice 
were immunized once unless otherwise stated. Adult control mice (6-8 weeks old) were 
immunized in both rear footpads (10ul/footpad) after being anesthetized by i.p. injection with a 
4/1 mixture (vol/vol) of ketamine (50 µg/g body weight) and xylazine (15 µg/g body weight). 
Mice were observed daily for a week for any adverse reaction to the immunization. 
 
Flu challenge 
The mouse flu challenge model used here has been described elsewhere (200). Three 
weeks after neonatal immunization, mice were challenged with 106 EID50 (50% egg infectious 
dose) of influenza virus strain PR/8/34 (Charles River, MA). The challenge dose represented the 
lowest dose that was 100% lethal in control mice immunized with diluent, and was optimized in 
a separate experiment. The virus was diluted in a total volume of 50µl, and 25µl was introduced 
into each nare under light isoflurane anesthesia. Mice were observed for 11 days for weight, 
morbidity, and mortality. The animals were monitored for clinical signs of disease including 
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ruffling, hunching, signs of dehydration (concave dorsal surface), and reduced spontaneous 
mobility. To assess protection from post-challenge influenza virus replication in the nose, mice 
were neonatally immunized, and five weeks later, mice were challenged intranasally with 106 
EID50 of influenza virus strain PR/8/34. At 48 h post challenge, mice were euthanized and nasal 
tissues were harvested from the tip of the nose to the anterior of the eye sockets, as described 
before (286, 327). Nasal tissue was collected in 10% FBS media and centrifuged, followed by 
storage in Trizol at -80°C until RNA isolation.  
 
RNA Isolation & Real-time PCR 
RNA extraction from nasal tissues was performed using the PureLink™ RNA Mini Kit 
(Ambion) according to the manufacturer’s protocol. RNA samples were then treated with DNase 
using the TURBO DNA-free™ kit (Ambion), following the manufacturer’s protocol. 
Quantification of PR8 HA negative strand RNA levels in the nasal tissues was performed by RT-
PCR as has been described previously (328). Briefly, cDNAs were prepared using reverse-
transcription with oligo(dT). RT-PCR was performed using TaqMan gene expression assays 
(Applied Biosystems) and gene-specific primers & probes (Life Technologies). The samples 
were then run on an ABI Prism 7000 real-time PCR system. During each reaction, a cycle 
threshold (CT) value for the target gene of interest was generated, which was then normalized to 
the CT value of the housekeeping gene (glyceraldehyde-3-phosphate dehydrogenase; GAPDH) 
yielding a ∆CT value. The ∆CT value of the nVRP-infected sample was then subtracted from the 
∆CT value of the antigen-only sample, resulting in a ∆∆CT value. Fold increase in mRNA 
expression in nVRP group relative to the expression level in antigen-only group were determined 
by using the formula 2∆∆CT. 
 
 69 
The HA-specific primers (forward: ACTGGACCTTGCTAAAACCC [starting at nt772]; 
reverse: CATTGATGC GTTTGAGGTGATG) & probes (/56-
FAM/CCCAAAGCC/ZEN/TCTACTCAGTGCGAA A/3IABkFQ/) for RT-PCR were designed 
and obtained from Integrated DNA Technologies (IDT). Additionally, PR8 HA negative strand 
RNA standards were prepared from the influenza virus stock used for infection and were run on 
each sample plate. For the analysis, CT value from each sample was plotted on the standard curve 
to obtain PR8 viral titer. All CT values were normalized to the housekeeping gene 18S. 
 
Analysis of antigen-specific IgG in serum and IgA in fecal extracts by ELISA 
Mouse sera was collected at 3, 6, 9, and 15 weeks after immunization and stored at -
20°C. For preparation of fecal extracts, fecal pellets collected 10-14 days after boost were 
suspended at 0.2 g/ml and disrupted by vortex mixing at 4°C in PBS containing 10% goat serum 
and 1X protease inhibitors (Roche; product number 11873580001). Samples were centrifuged, 
and supernatants were filtered through 0.22µm filters. Antigen-specific IgG and IgA antibodies 
were detected by ELISA on 96-well high binding plates (Thermo Scientific) coated with 4µg/ml 
iFlu in PBS. Sera and fecal extracts were added to plates in serial dilutions. Antigen-specific 
antibodies were detected with horseradish peroxidase conjugated antibodies specific for mouse 
IgG (Southern Biotech) or mouse-IgA (Southern Biotech) followed by addition of SureBlue 
(TMB Microwell Peroxidase Substrate; KPL) for 30 min. Endpoint titers were determined as the 
last sample dilution that generated an OD450 reading of greater than 0.2. For determination of 
total IgA levels in fecal extracts, 96-well plates were coated with 0.4µg/ml rabbit anti-mouse-
IgA (Invitrogen), ELISAs were performed as above, and a standard curve generated from 
dilutions of purified murine IgA (Sigma). This standard curve was used to determine the 
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concentration of both antigen-specific and total IgA in fecal extracts. 
 
Hemagglutination inhibition assay 
Flu-specific Hemagglutination inhibition assay (HAI) has been described elsewhere 
(Current Protocols in Immunology (2001) 19.11.1-19.11.32). Complement was inactivated by 
heating the serum sample at 56°C for 30 min. Mouse serum was then pre-adsorbed with 1% 
suspension of chicken red blood cells (CRBCs) resulting in a 1:5 dilution. Briefly, four 
hemagglutination units (HAU) of influenza virus strain PR8 in 50µl were mixed with 2-fold 
serial dilutions of pre-adsorbed mouse serum (50µl per dilution) and incubated at room 
temperature for 30 min (starting dilution 1:10). Fifty microliters of a 1% suspension of CRBCs 
was then added to each well. In serum dilutions with anti-HA antibody, virus was bound by 
antibody and was not available to agglutinate the CRBCs. The maximal reciprocal serum dilution 
where agglutination was completely inhibited is reported as the HAI titer. 
 
IFNαβ  bioassay 
The levels of biologically active type I IFN in mouse sera were determined using an 
interferon bioassay as previously described (329). Briefly, L929 mouse fibroblasts cells were 
seeded in 96 well plates. Mouse serum samples, including the standards, were acidified to a 
pH of 2.0 overnight, then neutralized to pH of 7, and added to cells in serial two-fold dilutions. 
After 24 hr incubation, 105 PFU of encephalomyocarditis virus (EMCV) was added to each well. 
Twenty-four hours post-infection, cell viability was determined using 3-(4, 5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma), and the absorbance was read on a 
microplate reader at 570 nm. To obtain type I IFN value in international units (IU/ml), the 
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absorbance from each sample was compared to a dilution series of IFNα standard (BEI; NR-
3076) present in each plate. 
 
Surface staining of cells from Draining Lymph Nodes (DLN) 
At the indicated time points, both draining popliteal lymph nodes from each animal were 
harvested, combined and homogenized through 40µm cell strainers. Cells were washed, counted 
by hemocytometer and stained at 4°C for desired surface receptors with a selection of the 
following fluorochrome-conjugated antibodies specific for CD3, CD4, CD8, CD11b, CD11c, 
CD40, CD80, CD86, MHCII (eBioscience), Ly-6G and Ly-6C (BD Bioscience) in 1% 
BSA/PBS. After staining, cells were washed and then fixed in 2% paraformaldehyde in PBS for 
15 min at room temperature. Cells were analyzed on an Accuri™ C6 Flow Cytometer (BD). 
 
IFN-γ  enzyme-linked immunospot (ELISPOT) assay 
IFN-γ ELISPOT assay was performed to measure influenza PR8 HA-specific IFN-γ-
secreting CD4 and CD8 cells in the popliteal draining lymph node and spleen of immunized 
mice. Mouse IFN-γ capture antibody (R&D Systems) was incubated on nitrocellulose membrane 
plates (96 well; Millipore) overnight at 4°C. Before the addition of cells, the plates were washed 
and blocked for at least 2 h with complete RPMI-10 (10% fetal bovine serum) at 37°C. Single 
cell suspensions in RPMI-10 (2.5×105 or 5×105 cells per well) from either popliteal draining 
lymph node or spleen were then added to the plates. Additionally, feeder cells (2.5×105 cells per 
well) from a naïve adult BALB/c mouse spleen were added to all wells. Finally, CD4 (HA 110-
120; SFERFEIFPKE) and CD8 (HA 518-526; IYSTVASSL) immunodominant HA peptides 
from AnaSpec were added to the appropriate cells for 36 hrs. Cells were removed from plates 
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and washed, a biotinylated mouse IFN-γ detection antibody (R&D Systems) was added to the 
plates, and the plates were incubated for another 36 h at 4°C. Membranes were again washed, 
incubated with a streptavidin–alkaline phosphatase conjugate for 2 h at RT. Plates were washed, 
and spots were developed following addition of BCIP/NBT substrate. Plates were scanned by 
Cellular Technologies Ltd. [Shaker Heights, OH]. Assay background values were obtained from 
sample wells with no peptide/protein stimulation and were subtracted from the values obtained 
with the influenza HA-peptide. Data are normalized to the number of antigen-specific IFN-γ-
secreting-cells per 106 cells. 
 
Tissue Culture Infectious Dose 50 (TCID50) Assay 
Virus titers in the lungs were determined by TCID50 assay on MDCK cells. Lungs 
collected on day 3 post-challenge were homogenized, serially diluted 10-fold, and then added in 
quadruplicate to cells in a 96-well plate. After 48 h incubation, an influenza hemagglutination 
assay (HA) using 5% chicken red blood cells was performed on the media from each well. 
TCID50 titers were determined using the Reed and Muench calculator. 
 
Multiplex analysis for cytokine expression in the DLN 
To determine cytokine levels in the DLN of mice immunized with iFlu alone or with 
nVRP, the draining popliteal lymph nodes from each mouse were harvested, combined and 
placed in 100µl of PBS containing 1X protease inhibitors (Roche; product number 
11873580001). The lymph nodes were mechanically homogenized with a pestle, followed by 
centrifugation at 4°C. Supernatant was transferred to another tube and frozen on dry ice. 
Cytokine levels in the samples were determined by Luminex-based multiplex assay. For one 
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experiment, levels of 18 cytokines were tested using the Milliplex MAP Mouse 
Cytokine/Chemokine Magnetic Bead Panel (EMD Millipore, Billerica, MA). The assay was 
performed by the Center for Gastrointestinal Biology and Disease's Immunotechnologies Core at 
the University of North Carolina at Chapel Hill. Multianalyte profiling was performed on a Bio-
Plex 200 system with an XY platform and high-throughput fluidics (Bio-Rad Laboratories, 
Hercules, CA). Calibration and validation microspheres for classification and reporter readings, 
as well as optics and fluidics verification, were also obtained from Bio-Rad. The instrument's 
sheath fluid was prepared from concentrate obtained from Luminex (Luminex Corporation, 
Austin, TX). Fluorescence data was acquired using Bio-Plex Manager 6.0 software, and all 
cytokines were successfully detected. Data analysis was performed using the same software, and 
a best-fit standard curve was obtained using either four- or five-parameter regression, from 
which the sample concentrations were derived. Cytokines that were undetectable were assigned a 
value of half of the lowest limit of detection as listed in the product manual. 
 
Statistical analysis 
Antibody titers and cytokine values were evaluated for statistically significant differences 
by either the ANOVA or Mann–Whitney test (GraphPad Prism). Statistical significance is 
reported as follows (*, p < 0.05; **, p < 0.01; ***, p < 0.001) 
 
3.4. RESULTS 
GVI3000 safely enhances humoral immune responses to inactivated flu (iFlu) in neonatal 
mice 
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To determine the adjuvant effect of GVI3000 on humoral responses to iFlu in neonatal 
mice, we assessed the magnitude, duration and quality of serum antibodies as well as induction 
of fecal antibody responses by iFlu alone or formulated with the GVI3000 adjuvant. Seven-day 
old BALB/c mice from one litter received a single immunization with 2µg of iFlu mixed with 
GVI3000 (105IU) while mice from a second litter were immunized with 2µg of iFlu only. Mice 
were monitored daily for local reactogenicity, morbidity and mortality. No adverse effects of 
immunization with iFlu alone or iFlu+GVI3000 were observed. Over the past several years 
approximately 2,000 adult mice and over 350 neonatal mice have been immunized with 
GVI3000 adjuvant without any observable signs of adverse reaction (268, 286, 287, 290, 327, 
330, 331)(Daniel Tonkin, Benjamic Steil, and Patricia Jorquera, personal communications). Flu-
specific IgG ELISA antibody titers in the iFlu-only group were modest and did not increase 
between 6 and 15 weeks post immunization (Figure 3.1A). In the GVI3000-adjuvanted group, 
the titers were significantly higher for all time-points tested compared to the iFlu-only group. 
From week 6 to week 15, the titers in GVI3000-adjuvanted mice continued to increase 
significantly (p<0.05) compared to week 3 (Figure 3.1A). Additionally, week 15 titers were 
significantly higher compared to week 6. The flu-specific IgG2a titers (indicator of TH1 
response) in the GVI3000-adjuvanted immunization group were significantly higher at 3, 6 and 
15 weeks (Figure 3.1B), while the IgG1 (indicator of Th2 response) titers were comparable 
between the groups (Figure 3.1C), suggesting that the GVI3000 adjuvant-mediated enhanced 
IgG response was predominantly in the IgG2a subclass. We performed our studies in BALB/c 
strain of mice, although previous results from our lab has shown that adult C57BL/6, 129 Sv/Ev, 
and other strains of mice produce a similar TH1-biased response upon GVI3000 immunization. 
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Previous studies have suggested the important role mucosal immunity plays in protecting 
against influenza virus, which primarily infects and provokes inflammation at respiratory 
mucosal sites (332). A unique feature of the GVI3000 adjuvant is its ability to induce—in adult 
mice—an antigen-specific mucosal IgA antibody response after a non-mucosal route of 
immunization (286, 327). We chose to measure the IgA response in the fecal pellets of 
immunized mice as IgA detection is more reliable and unambiguous measure of mucosal 
response compared to nasal or tracheal lavages. Additionally, it is known that mice have a 
common mucosal system, in which responses at one mucosal tissue likely mirrors those in other 
mucosal sites (333). Published studies in adult BALB/c mice have shown that induction of 
antigen-specific IgA in GVI3000-adjuvanted mice was significantly enhanced in fecal extracts 
similar to the increase in the nasal epithelium (286, 330). To address whether GVI3000 can 
prime the induction of antigen-specific mucosal IgA in early life immunizations, neonatal mice 
were primed with iFlu alone or iFlu + GVI3000, and ten weeks later, they were boosted with iFlu 
antigen only. The amount (ng of flu-specific IgA / µg of total IgA) of flu-specific IgA antibody 
found in fecal materials 10 days after the boost was measured by ELISA (Figure 3.1D). 
Presenting the IgA data as (ng of flu-specific IgA / µg of total IgA) allows for normalization of 
the fecal pellet size, which can vary between mice groups, genders, and within the same group 
sampled at different times, making it a reliable and accurate measure (334). While the signal for 
iFlu-only induction of IgA was at the background level, a significantly higher amount of flu-
specific IgA was observed in mice that had GVI3000 adjuvant in the prime. Importantly, the 
amount of flu-specific IgA in the adjuvanted group was not significantly lower than that found in 
adult mice (1.59 ng in neonates compared to 1.74 ng flu-specific IgA per µg total IgA in adults), 
when mice from both age groups were compared in the same experiment (data not shown). 
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To further assess the quality of the flu-specific antibodies being induced, we measured 
the ability of the antibodies in the sera to inhibit hemagglutination of chicken red blood cells 
using an HA binding inhibition assay (HAI). We included an experimental group adjuvanted 
with alum (Alhydrogel, 1:5), a well-characterized benchmark adjuvant, formulated as indicated 
by the manufacturers. Six weeks after immunization, HAI titers in the GVI3000 adjuvanted 
group (GMT = 24) were significantly higher than those in the iFlu-only group (GMT = 10). The 
HAI titer in the alum-adjuvanted group (GMT = 16) was not significantly different from either 
GVI3000 or no adjuvant groups (Figure 3.1E). At other time points (3 and 15 weeks), we did 
not observe any difference in HAI titers between the immunization groups (data not shown). 
 In summary, GVI3000 adjuvant significantly enhanced antibody responses to iFlu in 
neonatally immunized mice. Enhanced serum antibodies were mostly of the IgG2a class and had 
HAI activity. While antibody titers continued to increase during the 15 weeks of study, these 
titers were of much lower magnitude compare to those induced by the same vaccine regime in 
adult mice (unpublished observation). While this was true for serum antibodies after one dose, 
the ability of the adjuvant to prime a mucosal response seemed as effective in neonates as in 
adults.  
 
GVI3000 adjuvant induces antigen-specific CD4 and CD8 T-cells after a single 
immunization in neonatal mice 
While the contribution of T-cell immunity to protection against influenza remains a 
matter of debate, the flu model was utilized to determine whether GVI3000 can enhance the 
induction of antigen-specific T-cells in neonatal mice. We chose to understand the T-cell 
responses in the DLN (popliteal) as opposed to the more distal LN (such as mediastinal). T-cell 
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responses are present in distal LNs at reduced but still detectable levels, relative to DLN 
responses. In these initial neonatal studies of immunity induced by GVI3000 it was prudent to 
first evaluate responses in the DLN where we anticipate the most robust response, with the 
expectation that immunity detected in one tissue will correlate with immune memory throughout 
the animal. Groups of three 7-day old mice were immunized in both rear footpads with iFlu 
alone (2µg), or iFlu mixed with GVI3000 (105IU). In this experiment, a group adjuvanted with 
alum also was included. Eight days after immunization, animals were sacrificed and single cell 
suspensions were prepared from the pooled (2 per mouse) popliteal DLN. Cells were evaluated 
for the presence of IFNγ-secreting CD8 and CD4 T-cells following stimulation with 
immunodominant HA peptides. We chose to detect HA-specific T-cells instead of other T-cells 
described in literature (such as nucleoprotein, NP) as we were not sure which proteins, other than 
HA, were intact in the inactivated influenza antigen. Furthermore, based on our experience, adult 
BALB/c mice are capable of inducing T-cells specific for multiple antigens after a multivalent 
immunization, indicating that the T-cell response will most likely be not limited to HA antigen 
only. Animals receiving iFlu alone produced undetectable to very low levels of flu-specific CD4+ 
and CD8+ T-cells.  However, iFlu formulated with GVI3000 adjuvant resulted in a significant 
increase of both CD4+ and CD8+ T cells (Figure 3.2). Although the alum group had low but 
detectable amounts of CD4+ T-cells and CD8+ T-cells, they were significantly lower than the 
GVI3000 immunized group. Taken together, these results strongly suggest that GVI3000 
adjuvant can promote the induction of a CD8+ T cell response in the TH2-polarized neonatal 
immune system.  
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Neonatal mice immunized with GVI3000-adjuvanted iFlu vaccine have reduced morbidity 
and mortality and reduced early post challenge virus titers in nose and lungs 
Two independent flu challenge experiments were performed. In the first experiment, four 
litters of mice were immunized on day 7 post birth with either PBS (N=8), iFlu-only (N=5), iFlu 
with GVI3000 (105IU; N=5) or iFlu formulated with alum (1:5; N=7). Three weeks after 
immunization, the mice received a lethal challenge by intranasal inoculation with 106 EID50 of 
Influenza A/PR/8/34. The mice were monitored daily for 11 days for weight loss, morbidity, and 
mortality. Figure 3.3A shows the survival curves. All the PBS-immunized control mice 
succumbed to the challenge. All mice that received a single GVI3000-adjuvated immunization 
were protected. Three out of 7 mice that received alum-adjuvanted iFlu antigen survived, while 2 
out of 5 mice in the iFlu-only immunized group survived. A repeat challenge experiment using a 
different stock of live influenza virus was done with three immunization groups: PBS control 
(N=6), iFlu only (N=11) and iFlu with GVI3000 (N=11). In this experiment mice were 
monitored for 25 days. No protection was observed in PBS control mice or iFlu-only immunized 
mice, while 7 out of 11 mice survived in the GVI3000-adjuvanted group (Figure 3.3B). Taken 
together, the two experiments demonstrate that the GVI3000-adjuvanted vaccine outperforms 
vaccine alone, but that the vaccine adjuvanted with alum was no more protective than vaccine 
alone. Post-challenge weight change relative to the starting weight is shown in Figures 3.3C-F 
for the first challenge experiment. In the GVI3000 adjuvant group, one mouse showed no weight 
loss, although the remaining animals lost ~12% of their starting weight on average before 
recovering completely; none of the mice showed any overt clinical signs of disease. In the alum 
group, the three mice that survived the challenge showed ruffling and hunching. Taken together, 
these results demonstrate that GVI3000-adjuvanted vaccine mediated significant protection from 
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influenza induced morbidity and mortality in neonates. 
 The effect of neonatal immunization on replication of challenge virus in the nasal tissue 
was detected at 48 h post-challenge by real-time PCR. There was a significant decrease in virus 
titer in the GVI3000- and the alum-adjuvanted groups compared to the iFlu-only group when 
mice were challenged 5 weeks post neonatal immunization (Figure 3.4A). Additionally, we 
measured virus titers in the lung on day 3 post-challenge. Mice that received the GVI3000-
adjuvanted vaccine showed no detectable TCID50 titers (level of detection = 43.1 TCID50/ml), 
which was a reduction of over two orders of magnitude compared to titers from PBS (p<0.01), 
iFlu only (p<0.01) and iFlu+alum groups (p<0.05) (Figure 3.4B). Although titers in the alum-
adjuvanted group were significantly higher compared to GVI3000-adjuvanted mice, they were 
significantly lower compared to iFlu (p<0.05). 
These results are consistent with the survival data shown in Figure 3, and suggest that although 
alum provides comparable protection early in the nose, GVI3000 adjuvant is better at preventing 
replication in the lungs as well as preventing morbidity and mortality.  
 
GVI3000 primarily targets DCs and promotes recruitment of multiple immune cell types 
into the DLNs of neonatal mice 
GVI3000 adjuvant induces recruitment and infection of APCs in the DLN of adult mice. 
Although DCs are the primary targets of GVI3000, other immune cells are also targeted and it is 
likely that the targeting of DCs and other APCs play a role in the adjuvant effect in adult mice 
(268, 327). Further investigation led to the findings that inflammatory DCs, although rare in the 
DLNs during steady state, were rapidly recruited to the site of inflammation and were the subsets 
that had the largest fold-increase in immune cell population (268).   
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 Given that the neonatal immune response is limited in part by a reduced numbers of 
immune cells, one important question was to determine the targets of GVI3000 in neonatal mice. 
Groups of five mice were immunized in both footpads with PBS, iFlu (1µg) alone, or iFlu 
together with GVI3000 expressing GFP (GVI3000-GFP; 105IU). GVI3000-GFP is identical to 
GVI3000 except that a subgenomic promoter driving the expression of GFP has been added 
downstream of NSP4. As GVI3000 cannot propagate to surrounding cells, and as infection of 
and RNA replication in the target cells must occur to allow GFP expression, cells containing 
GFP unequivocally identify GVI3000 target cells that support RNA replication (286). At 12hpi, 
both popliteal DLNs were harvested from each neonatal mouse, combined and homogenized. 
First, we measured the cellularity of the DLN, or total number of cells per lymph node by flow 
cytometry, using the volume analyzed by Accuri™ C6 Flow Cytometer (BD) and back-
calculating the number of cells in the starting sample. Neonates immunized with iFlu mixed with 
GVI3000-GFP had significantly higher DLN cellularity compared to mice immunized with iFlu 
alone (Figure 3.5A). Previously published results in adult BALB/c mice showed a similar 2-3 
fold increase in DLN cellularity in the presence of GVI3000 (268). Infiltrating immune cells 
were identified by antibody staining for the following surface markers: conventional DCs (cDCs; 
CD11c+, CD11b-), inflammatory DCs (iDCs; CD11c+, Ly6C-hi) (Figure 3.5B), macrophages 
(CD11b+, CD11c-), and neutrophils (Ly6G+). Except for the cDC population, which did not 
differ significantly between the groups, all immune cell types measured (iDCs, neutrophils, and 
macrophages) showed significant population increases at 12hpi (Figure 3.5C). The same was 
true for immune cell populations (B- and T-cells) at 24 hpi (data not shown). Inflammatory DCs 
showed the most significant increase (11× fold increase; p = 0.0079), and a similar increase was 
observed at 12, 18 and 24 hpi (data not shown). 
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 To determine which cell populations were targeted by GVI3000 in the neonates, GFP 
positive cells were quantified in the DLN at 18 hpi. Although GFP expression was observed in 
several different immune cell types, iDCs were the predominant target of GVI3000 replication 
(Figure 3.5D). Up to two-thirds of all cells expressing GFP were iDCs. Conventional DCs, 
macrophages, and neutrophils each represented 6-8% of all infected cells. Studies in adult 
BALB/c mice showed a similar infection pattern of cell populations (268). Approximately 11% 
of the GFP positive cells were unidentified.  Previous reports and  unpublished observations in 
adult mice suggest  that these unidentified cells may be T-cells, B-cells, and NK cells (268).  
 
GVI3000 adjuvant activates neonatal dendritic cells  
The activation and maturation of infected and bystander DCs was identified by measuring 
the early in vivo expression of MHCII and the co-stimulatory molecules CD40, CD80, and 
CD86. Three groups of four neonatal mice were immunized with: PBS, iFlu (1µg) alone, or iFlu 
with GVI3000-GFP (105IU). GVI3000-GFP served as an adjuvant to iFlu and as an expression 
vector for GFP. This marker was used to distinguish the activation state of infected vs. bystander 
DCs in the GVI3000 adjuvanted group. Both DLNs were harvested from each mouse, 
homogenized, and stained at 18hpi. After gating for inflammatory DCs, the cells were further 
gated for GFP expression and analyzed for MHCII, CD40, CD80, and CD86 (Figure 6). The 
expression level of all activation/co-stimulatory markers (indicated by Mean Fluorescence 
Intensity, MFI) observed in the iFlu-only group did not differ from the PBS immunized group. 
There were no differences in the MFI of activation/co-stimulatory markers between the iDCs of 
the antigen-only group and the GFP-negative iDCs in GVI3000-GFP immunized group (Figure 
3.6A-D). However, iDCs that were GFP-positive (i.e. GVI3000 infected) had significantly higher 
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MHCII, CD40, CD80, and CD86 MFIs. The trend was similar for cDCs, with MHCII, CD80, 
and CD86 showing significantly higher GFP-positive cells compared to GFP-negative cells and 
cDCs in the antigen-only immunized group (data not shown). We believe that the GFP-positive 
cells detected in this experiment were due to direct infection by GVI3000-GFP and not due to 
phagocytosis of infected cells. It has been previously demonstrated in adult BALB/c mice that 
GVI3000-GFP infection leads to uniform GFP signaling in the cytoplasm instead of punctate 
GFP signaling, which would have indicated phagocytosis (198) (Laura White, unpublished 
observations).  
In summary, as seen in adult mice, GVI3000 targets and activates neonatal iDCs and 
cDCs. Bystander iDCs were not activated at 18 h in the DLN of neonates receiving GVI3000 
adjuvant. This seems to be different to what was reported ex vivo in bone marrow-derived DCs 
from adult mice , where bystander DCs were also activated (303).   
 
GVI3000 induces several inflammatory cytokines in neonatal mice early after 
immunization 
Studies in adult mice have shown that the GVI3000 adjuvant can significantly enhance 
the inflammatory cytokine/chemokine response after immunization (287). These effector 
molecules appear within a few hours and return to basal levels within 24 to 36 hours after 
exposure to GVI3000. It has been suggested that human neonatal plasmacytoid DCs are 
incapable of inducing Type I IFNs similar to adult levels (335). Systemic type I IFN was induced 
to a high level in serum by 6 hpi in neonatal mice immunized with GVI3000-adjuvanted flu 
vaccine (Figure 3.7). Furthermore, the response remains significantly higher compared to 
antigen-only immunized mice at least until 24hpi. By 36 hpi, the level of type I IFN had ebbed to 
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near basal levels. The kinetics of type I IFN induction is similar for the two antigens tested (iFlu 
and Fluzone® 2011 vaccine). The levels and kinetics of these IFN responses were similar to 
those observed in control adult BALB/c mice (data not shown), indicating that 7-day old mice 
are capable of adult-like type I IFN innate immune responses to GVI3000-adjuvanted antigens, 
including both rapid induction and return to basal levels. 
To measure local induction of other inflammatory cytokines in immunized neonatal mice, 
an 18-plex assay was performed measuring levels of cytokine/chemokine proteins in the 
popliteal DLN 12 hrs after footpad immunization (Table 3.1). Several cytokines had 20 to 1,500 
fold increases in the GVI3000 adjuvanted group compared to antigen-only, including IFNγ, IP-
10, MCP-1, and MIG. Another group of cytokines, including G-CSF, MIP-1β, and RANTES 
also were higher by 5 to 15 fold at 12 hpi. Adult DLNs analyzed at the same time showed a very 
similar trend, qualitatively and quantitatively, with GM-CSF, IL-1β, and MIP-1β also showing 
>5-fold increases. 
 
3.5. DISCUSSION 
The data presented here demonstrates the feasibility of a new class of adjuvants for early 
life vaccination. The non-propagating alphavirus replicon particle adjuvant, GVI3000, was safe 
in neonatal mice, and when co-delivered with iFlu antigen, enhanced multiple effector functions 
of the neonatal immune system including antigen-specific IgG2a antibodies, mucosal IgA, and 
CD4+ and CD8+ T cells, indicating a shift from a TH2-polarized to a balanced TH1/TH2 immune 
response that potentiated a significant increase in protection from a lethal influenza challenge. 
Many of the innate immune response cytokines and chemokines induced by GVI3000 in adult 
mice also were induced in neonatal animals. As in adults, neonatal DCs were targeted and 
 
 84 
activated by the adjuvant particles, and a high proportion of inflammatory cells were recruited to 
the DLN. The relevance of these findings are several fold: First, it is the first report, to our 
knowledge, to show a protective immune response to influenza in a neonatal animal model, 
suggesting that the alphavirus adjuvants presumptively could be used in infants. Second, a single 
immunization with the GVI3000-adjuvanted vaccine was sufficient to protect in this model, 
which represents a significant improvement over existing early life vaccines that require multiple 
immunizations, including current vaccines for influenza.  This is especially relevant in poor 
countries, where birth and early life are often the only opportunities for patient contact with 
healthcare providers. Third, GVI3000 activates neonatal innate immunity and enhances all arms 
of the adaptive immune system, including the humoral, cellular and mucosal compartments. 
 It is well established from studies in animal models and humans that the immune 
response to vaccination in neonates is weaker than that of adults (68, 70, 101, 296). It is 
characterized by i) serum antibody titers that are lower in magnitude (36, 297) and of shorter 
duration (298, 299), ii) APCs that show reduced upregulation of co-stimulatory molecules (69), 
iii) T-cells that exhibit a TH2 bias, secreting high levels of IL-4 and low amounts of IFNγ (68, 
115-118), and iv) significantly limited CTL responses to vaccines (reviewed in reference (70)). 
In this study, we confirmed the age-related deficiencies in neonatal mice relative to adults in 
different areas of the adaptive and innate immune responses. After a single immunization IgG 
Ab titers in neonates were significantly lower compared to those induced in adult mice, and HAI 
titers, while induced in adults, were undetectable in the neonatal mice. In addition, upon 
vaccination with antigen only, neonatal mice showed approximately 20 fold fewer cells in the 
popliteal DLN compared to adults, including reduced numbers of iDCs, cDCs, neutrophils and 
macrophages. Furthermore, the neonatal response to antigen alone was characterized by lower 
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expression of most cytokines in a panel of 18 inflammatory cytokines and chemokines examined. 
Other deficiencies observed in the neonatal responses to iFlu, such as minimal to undetectable 
induction of CD4+ or CD8+ T cells and no mucosal IgA priming, were also present in the adult 
responses, and therefore were in part determined by the nature of the antigen. 
 Although the overall magnitude of the serum Ab titers in the GVI3000-adjuvanted groups 
were still lower in neonates compared to adults, the GVI3000 adjuvant was responsible for a 
significant increase in flu-specific IgG antibodies, especially IgG2a, at 3, 6, and 15 weeks, and 
HAI Abs at 6 weeks after a single immunization. Additional experiment using an inactivated 
dengue virus antigen (serotype 4; iDENV4) also showed significantly higher dengue-specific 
total IgG and IgG2a antibodies early after immunization (Supplementary Figure 1). Comparing 
with alum-adjuvanted iDENV4, we observed that while both adjuvanted neonatal mice groups 
had similar total IgG antibodies, GVI3000-adjuvanted mice primarily had increase in IgG2a 
subclass, while alum had increase in IgG1 subclass. In the mucosal compartment, antigen-
specific IgA was induced after two immunizations only when GVI3000 was present in the 
priming inoculation, with titers that were similar to those induced in mice primed as adults. Since 
we have previously demonstrated that unadjuvanted iFlu in adult mice does not induce mucosal 
IgA after one or two immunizations (Thompson and Johnston, unpublished), our data suggests 
that the induction of mucosal IgA in neonatally primed mice is due to the primary immunization 
and not to the antigen-only boost. The present study assumes that the fecal IgA was produced at 
the mucosal surface (336), as has been observed with iFlu in adults (290, 327). Therefore, the 
GVI3000 adjuvant may be of particular benefit in neonatal vaccines against mucosal pathogens. 
In the neonatal TH2-polarized immune response, antigen-specific, IFNg-producing T cells are 
poorly induced by immunization with non-replicating antigens (70). GVI3000 was able to 
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overcome this deficiency after one immunization.  
 The presence of GVI3000 also resulted in improvement of protection in the intranasal 
lethal challenge model. However, in the second challenge experiment (Figure 3B), not only the 
GVI3000-adjuvanted group, but also the control unadjuvanted group had a higher number of 
lethal infections compared to the first challenge experiment (Figure 3A), implying that the 
second challenge was more stringent than the first one. This can be explained as the two 
independent challenge experiments were performed with different challenge stocks (live 
influenza PR8) obtained separately from the same commercial vendor (Charles River, MA), and 
that it is not unexpected that minor differences in virus titers may result in differences in 
virulence. Our results show that while GVI3000-adjuvanted neonatal mice had significantly 
improved protection compared to mice immunized with iFlu only, the use of alum as an adjuvant 
did not improve protection, despite similar functional HAI antibody titers at 3 weeks post-
immunization. This implies that the improved protection mediated by GVI3000 may be 
attributed to immune effectors other than HAI antibodies. It has been shown previously that 
antibodies are effective in protection from homologous influenza virus challenge in adult mice 
(337-339). It is likely that in neonates, due to the weaker antibody response to iFlu (even with 
adjuvant) those antibody levels may not be sufficient for complete protection. Under these 
circumstances, and as suggested by our data, cellular and mucosal immune responses, if induced, 
could play a significant role in early life protection. 
 One of the reported deficiencies of the neonatal immune system is the limited quantity of 
immune cells available as compared to adults (68, 91, 135, 340-342). Consistent with this, our 
observations show that the cellularity of the popliteal DLN of an unimmunized 7-day old 
BALB/c mouse or an age-matched animal immunized with antigen-only was lower than a 6-
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week old adult mouse. In GVI3000-adjuvant inoculated neonatal mice we observed a significant 
2-3 fold increase of DLN cellularity, which was similar to the percentage increase in cellularity 
induced by GVI3000 in adult mice reported by Tonkin et al (268). Additionally, we observed 
that the total number of iDCs in GVI3000-adjuvanted neonatal DLN accounted for 
approximately 8% of the total number of cells in the DLN, while it was <2% in the adult DLN 
(268). The robust recruitment and targeting of iDCs suggests an important role for these cells in 
the mediation of the GVI3000 adjuvant effect. DCs have been shown to be sufficient to mediate 
the GVI3000 adjuvant effect (268), but it is possible that other cell types complement the role of 
iDCs. We therefore cannot definitively point to a specific cell type that mediates the immune 
enhancement driven by GVI3000, but we predict that the ability of GVI3000 to trigger cell 
recruitment in neonates is an important component of this outcome.   
We hypothesized that, as in adult mice, the adjuvant effect of GVI3000 in neonates was 
associated with the ability to i) target and activate neonatal DCs, and ii) induce a robust TH1 
innate immune response. Previous in vitro studies using VEE replicon particles (VRP) 
expressing GFP to infect adult human (303) and murine BMDCs (325) showed an upregulation 
in co-stimulatory molecules CD40, CD80, and CD86. Additional studies using VRP-transduced 
human DCs showed DC maturation, secretion of proinflammatory cytokines, and significant 
expansion of antigen-specific T-cells (303). In our in vivo system, we observed that both 
conventional and inflammatory DCs had significantly higher expression of MHCII, CD40, 
CD80, and CD86 after administration of GVI3000. However, this increase was observed only in 
DCs that were GVI3000-positive (GFP positive), but not in the “bystander DCs”. These results 
indicate that the infected DCs are the primary driver of the adjuvant effect of GVI3000 in the 
neonates. This finding is in contrast to what was described in in vitro studies of adult DCs, where 
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both GVI3000 infected and bystander DCs showed up-regulation of those markers (303). We can 
speculate that the absence of activation of by-stander DCs in neonates at the time points 
examined may contribute to the reduced magnitude of the immune responses in neonates 
compared to adults. On the other hand, we cannot rule out that the “by-stander” DCs would show 
a significant increase in expression of maturation and costimulatory molecules if examined at 
later times, after 18 h, as was observed in vitro at 24 h post-infection of human DCs (303). 
Further studies are needed to better understand the kinetics of DC maturation and expression of 
costimulatory molecules in vivo and its effect on T-cell response. 
 Our second hypothesis was that the significantly improved humoral and cellular 
GVI3000-adjuvant effect was associated with a robust TH1 cytokine response initiated early after 
immunization. Consistent with this hypothesis a rapid, strong, and self-limited innate immune 
response was observed locally and systemically upon GVI3000 immunization, based on the rapid 
cytokine induction. The innate immune responses were consistent even when other antigens were 
used (data not shown), indicating that the GVI3000 adjuvant was primarily responsible for the 
enhanced response. 
 Our results indicate that GVI3000 can induce adult-like systemic and local innate 
immune responses in neonates. Although type I IFN function is not required for the adjuvant 
activity of GVI3000 in adult mice (330), it is an indicator of GVI3000 RNA replication and of a 
robust innate immune response. The observation that neonatal mice had adult-level type I IFN 
responses to GVI3000 indicates that the adjuvant may overcome the impairment in type I IFN 
induction observed in newborn cord blood (343, 344). Additionally, the type I IFN response was 
systemic, peaking at 12 h post immunization and falling to background level by 36 hrs. This 
demonstrates that the GVI3000-mediated inflammatory response is transient, reducing any 
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chance of prolonged inflammation or toxicity. One of the reasons for immunizing neonatal mice 
through the footpad was the ability to investigate the process of inflammation in a single DLN. 
Cytokine expression analysis in the DLN further supported our second hypothesis in that the 
enhanced cellular immune response is preceded by a TH1-promoting innate immune response. As 
with systemic Type I IFN expression, a similar pattern of peak expression of most cytokines at 
12 hpi was observed with gradual reduction to background level by 36 hpi (data not shown). 
IFNγ is a hallmark of a TH1 response; however, its production is impaired in newborns as 
evidenced by lack of IFNγ induction in neonatal mice after subcutaneous injection of LPS (345). 
BCG vaccination is one of the few examples of vaccines that can induce adult-like IFNγ as has 
been demonstrated in CD4 T-cells of two-month old human newborns—immunized at birth—
after stimulation with a mycobacterial purified protein derivative (94). IFNγ protein expression 
was rapidly upregulated in neonatal mice after GVI3000 inoculation, which induced an adult-like 
response (adult data not shown).  The IFNγ-responsive chemokine IP-10 (CXCL10) (346) was 
significantly upregulated in GVI3000 adjuvanted neonatal mice to a level similar to that in adult 
animals. As observed in adult mice, GVI3000 did not induce IL-12 protein expression, even 
though this cytokine is strongly associated with induction of IFNγ and a TH1 response. 
Therefore, further investigation is needed to elucidate the role of IL-12, or lack thereof, in the 
GVI3000 adjuvant mode of action. Other cytokines that were upregulated, but do not have a 
clearly defined role in TH1 responses, were MCP-1, MIG, and MIP-1β. Overall, the cytokine 
expression pattern between neonates and adults was quite similar, indicating i) neonates are 
capable of mounting an adult-like innate immune response, and ii) the mechanism whereby the 
GVI3000 adjuvant induces innate immune response may be similar in neonates and adults. 
 Improved technologies are urgently needed for vaccines against several infectious 
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diseases, especially for children in developing countries. This study demonstrates the potential of 
GVI3000 as an effective adjuvant for early life vaccination combined with currently available 
and future vaccines. 
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Figure 3.1 
 
Figure 3.1: GVI3000 is an effective adjuvant to iFlu after a single dose in mice immunized 
as neonates. 
Three to five 7-day old BALB/c mice per experimental group were primed through f.p. injection 
with iFlu (2µg) in the presence (gray bars) or absence (empty bars) of 105 IU of GVI3000. Three, 
6, 9, and 15 weeks after the immunization, flu-specific (A) IgG and, (B) IgG1 and IgG2a 
antibodies were measured in sera by ELISA. (C) GVI3000 induces mucosal immune response in 
neonatally primed mice. Five or six 7-day old BALB/c mice were primed through f.p. injection 
with iFlu (1µg) only (empty bars) or with 105 IU of GVI3000 (gray bars). Ten week post-prime 
all groups were boosted with iFlu (1µg) alone. Ten days post-boost, antigen-specific IgA were 
measured in fecal extracts by ELISA. IgA amount produced is presented as ng of flu-specific 
IgA / µg of total IgA. (D) Antibodies with Influenza hemagglutination inhibition activity were 
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measured by Hemagglutination Inhibition Assay (HAI) at 6 weeks after the immunization. All 
data are presented as the mean +/- SEM. *, p<0.05; **, p<0.01 compared with iFlu alone as 
determined by Mann-Whitney. 
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Figure 3.2 
 
Figure 3.2: GVI3000 adjuvant promotes flu-specific cellular immune response in neonatal 
mice DLN after a single neonatal immunization. 
Three 7-day old BALB/c mice were primed through both rear f.p. with iFlu (2µg) in the presence 
(gray bars) or absence (empty bars) of 105 IU of GVI3000. As a control adjuvant, three mice 
from one litter were immunized with alum (1:2 by volume; black bars). Eight days after 
immunization, both popliteal draining lymph nodes from each mouse were harvested and pooled. 
DLN cells from each experimental group were stimulated with immuonodominant CD4 and CD8 
HA peptides followed by IFNγ release ELISPOT assay. Data was normalized to the mock-
stimulated positive spots for each experimental group and graphed as number IFNγ positive spots 
per 106 DLN cells. Data are presented as the mean +/- SEM. *, p<0.05; **, p<0.01 compared 
with iFlu alone as determined by Mann-Whitney. 
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Figure 3.3 
 
Figure 3.3: GVI3000-adjuvanted iFlu protects neonatally immunized mice from a lethal 
influenza challenge. 
(A) Neonatal mice were immunized with iFlu only (N=5), or with either GVI3000 (105IU; N=5) 
or alum (1:5; N=7). Included in the challenge were PBS immunized mice (N=8). All mice were 
intranasally challenged with a lethal dose of 106 EID50 of Influenza A/PR/8/34 virus at 3 weeks 
after immunization. Mice were monitored for (A) mortality and (C-F) weight for 7 days after the 
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challenge. (B) Neonatal mice were immunized with iFlu only (N=11), or with GVI3000 (105IU; 
N=11). Included in the challenge were PBS immunized mice (N=6). All mice were intranasally 
challenged with a lethal dose of 106 EID50 of Influenza A/PR/8/34 virus at 3 weeks after 
immunization and monitored for survival. 
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Figure 3.4 
 
Figure 3.4: Viral titers in nasal tissues and lungs of challenged mice. 
Groups of 5 seven-day old mice were immunized with either iFlu (1µg) alone or with an 
adjuvant: GVI3000 (105IU) or alum (Alhydrogel 1:5). An additional PBS immunized group was 
included. Five weeks after the single immunization, mice were challenged intranasally with 106 
EID50 of Influenza A/PR/8/34. (A) Mice were euthanized 48 h post-challenge and nasal tissues 
collected in Trizol. Following RNA extraction, real-time PCR was done with PR8 HA 
primer/probes. CT values were plotted on PR8 HA standard curve to calculate virus titer. (B) 
Mice were euthanized 3 days post-challenge and their lung harvested. After homogenization of 
lung tissues, TCID50 assay was performed on MDCK cells. Cell supernatants were collected after 
48 h of incubation and hemagglutination assay was performed with 5% chicken red blood cells. 
TCID50/mL values were calculated using the Reed-Muench method. All data are presented as the 
mean +/- SEM. * p<0.05, ** p<0.01 as determined by Mann-Whitney. 
 
 
 
 
 
 
 97 
Figure 3.5 
 
 
Figure 3.5: GVI3000 enhances inflammation in the DLNs of neonatal mice. 
Five 7-day old BALB/c mice were immunized in both f.p. with PBS only (empty bars), and iFlu 
(1µg) in the presence (gray bars) or absence (black bars) of 105 IU of VRP-GFP. At 12hpi, both 
popliteal DLNs from each neonatal mouse were harvested, combined, and manually disrupted 
into single cell suspension. (A) DLN cellularity was assessed by using the volume analyzed by 
Accuri™ C6 Flow Cytometer (BD) and back-calculating the starting sample amount. (B) A 
representative histogram for inflammatory Dendritic cell gating, (C) Using fluorescent antibody 
staining, immune cells were stained for DCs (CD11c+), Inflammatory DCs (CD11c+, Ly6C-hi), 
Neutrophils (Ly6G+), and macrophages (CD11c-, CD11b+). Graph represents the total number 
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of each immune cell present in the DLN sample. (D) Cells that were positive for GFP expression 
were then gated for different immune cells’ surface markers. Data are presented as the mean +/- 
SEM. * p<0.05, ** p<0.01, and *** p<0.001 as determined by Mann-Whitney. 
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Figure 3.6 
 
Figure 3.6: Dendritic cells are activated in VRP-GFP adjuvanted mice. 
Three groups of four mice each were immunized with PBS, iFlu (2µg) only, or iFlu (2µg) with 
VRP-GFP (105IU). Immune cells from the DLN (two per mice per pool) were harvested and 
stained at 18 hpi for inflammatory DCs (CD11c+, Ly6C-hi). VRP-GFP adjuvanted group had 
both GFP-positive (black bars) and -negative (empty bars) DCs. Inflammatory DCs were gated 
for (A) MHCII, (B) CD40, (C) CD80, and (D) CD86 surface markers. Data are presented as the 
mean +/- SEM. * p<0.05, ** p<0.01, and *** p<0.001 as determined by Mann-Whitney. 
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Figure 3.7 
 
Figure 3.7: GVI3000 induces systemic Type I interferon immune response neonatal mice. 
At least four 7-day old BALB/c mice were immunized through f.p. with Ag (iFlu; 1µg) or Ag^ 
(Fluzone; 1µg) by itself (empty bars) or with 105 IU of GVI3000 (gray bars). At 3, 6, 12, 24, and 
36hpi mice were terminally bled. Type I IFN response was measured by IFN bioassay. Data are 
presented as the mean +/- SEM. *** p<0.001 as determined by Mann-Whitney. 
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Table 3.1 
Cytokine levels in the DLNs of neonatal mice at 12hpi (pg/mL±SEM). 
 
Footpad immunization of 7-day old mice. * indicates a significant difference of at least p <0.05. 
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Supplementary Figure 3.1 
 
Supplementary Figure 3.1: GVI3000 is an effective adjuvant to inactivated Dengue 
(serotype 4; iDENV4) after a single dose in mice immunized as neonates. 
Three to six 7-day old BALB/c mice per experimental group were primed through f.p. injection 
with iDENV4 (2µg) in the presence (gray bars) or absence (empty bars) of 105 IU of GVI3000 
adjuvant. A third group of mice were immunized with iDENV4 (2µg) adjuvanted with alum (1:2 
volume). Three weeks after the immunization, DENV4-specific Total IgG, IgG2a, and IgG1 
antibodies were measured in sera by ELISA. The limit of detection (LOD) for this assay was 
1:50 as indicated by the dashed line. Data below the LOD was assigned a value of 1:25, which is 
one dilution below the LOD. All data are presented as the mean +/- SEM. *, p<0.05 compared 
with iFlu alone as determined by Mann-Whitney.
 CHAPTER 4: DISCUSSION & FUTURE DIRECTIONS 
4.1. Contributions and impact to the field 
It started with a crude but effective smallpox vaccine in 1796, but the field of 
vaccinology has grown tremendously in the past two centuries. Vaccines remain one of the most 
important modern medical achievements. One disease, smallpox, has been eliminated, while 
others have been very successfully contained. The continued discoveries in understanding the 
pathogens, hosts, and their interaction has led to the development of novel treatment and 
prevention techniques for many diseases. To put a number on the lives saved and disease 
prevented (or their severity reduced) due to effective vaccination would, in my view, be 
underestimating the success. Probably due to the success of smallpox vaccines and others, in the 
late 1960s, the Surgeon General of the U.S., Dr. William H. Stewart, was (in)famously quoted as 
saying: “It is time to close the book on infectious diseases, and declare the war against 
pestilence won” (347). However, the fight against infectious diseases is still not over (and it 
probably never will). Although we have had success with traditional vaccination methods, 
continued development of safe, effective, and novel vaccine technologies will be important to 
combat infectious diseases. It is of further importance that the new vaccines provide protection in 
the most vulnerable of our population, including the very young. 
The challenges of immunization in early life are greater in many ways than in an adult. 
Researchers in the field are beginning to better understand the differences between neonates and 
adults in terms of how the innate and adaptive immune responses are induced and regulated. 
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Those differences favor tolerance, but leave the very young less equipped to defend against 
pathogens. It has now become clear that the neonatal immune system is capable of inducing 
adult-like responses if the appropriate pathways are stimulated (68, 309).  
The work presented in this thesis further supports those findings and contributes towards 
our understanding of how the induction of the innate and adaptive immune responses in neonatal 
mice compare to those in adult mice, and identifies pathways of the innate immune response that, 
when stimulated in the neonate, change the quality of the adaptive response.     
 Two different alphavirus-based vaccine platforms were used to show not only the 
induction of effective and protective immunity against two different infectious agents, influenza 
and dengue, but also as tools to better understand the induction of the neonatal immune response. 
In the VRP expression vector, the same replicon particle functions to deliver the antigen and to 
serve as innate immune-stimulant. On the other hand, in the VRP as adjuvant, the replicon 
particle only provides the danger signal function, while the antigen is not expressed from the 
replicon particle, but co-delivered as purified protein or inactivated virions. By separating the 
antigen delivery function from the adjuvant function in the VRP as adjuvant particles 
(GVI3000), we were able to demonstrate the role of the adjuvant function in the VRP, and start 
to understand how it mediates the changes in the quality and magnitude of the immune response 
in the neonate. We propose a model for how the adjuvant works in neonates in figure 4.1.  
 The work in this thesis suggests that a viral expression vector that operates by inducing a 
robust innate immune response would be able to overcome to some extent the lack of sufficient 
and protective immunity seen in neonates. This work should serve as a foundation for further 
research into the development of early life human vaccines for multiple pathogenic agents. 
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Figure 4.1. VRP expression vector and adjuvant particle can overcome impairments in the 
neonatal immune response. 
(A) Neonatal immune response to vaccines leads to inefficient antigen presentation and 
low expression of co-stimulatory molecules resulting in reduced expansion of T-cells, low 
antibody response, TH2-biased immunity, and insignificant cytotoxicity. (B) VRP as expression 
vector or adjuvants activate DCs to enhance antigen presentation and co-stimulatory molecule 
expression, leading to T-cell expansion and memory generation. Furthermore, there is efficient 
T-B cell interaction, a balanced TH1/TH2 response, and induction of cytotoxic CD8+ T-cells. 
VRP replicon particles can also induce mucosal immunity. VRPs infection does not lead to the 
detectable production of IL-12. 
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4.2. Immune induction by alphavirus-based vaccines and adjuvants in neonatal mice 
4.2.1. Humoral immune response 
It has been shown that vaccine-induced antibodies can play a protective role by either 
minimizing the spread of pathogens or eliminating them completely in several infectious disease 
models (12, 16-20). However, one of the main challenges of neonatal immunization is the 
induction of a potent antibody response. More specifically, the antibody response is delayed, of 
lower magnitude, short-lived, qualitatively different, has lower average affinity, and reduced 
heterogeneity (68). Additionally, the antibody response in early life is geared more towards a 
TH2 response (involved in allergic reactions and immune tolerance) at the cost of less pro-
inflammatory TH1 responses needed to combat intracellular pathogens (68, 307). Therefore, any 
vaccine-induced antibody response should be able to overcome these obstacles to induce a 
protective immune response in early life. In our studies, we observed that both VRP platforms 
induced an immune response in neonatal mice that was predominantly a TH1 response. Although 
it was not possible to measure this TH2 to TH1 shift in VRP vector studies, by separating the 
antigen delivery from the adjuvant function we were able to ask how the adjuvant particles 
modified the immune response induced to the co-delivered antigen. The GVI3000 adjuvant study 
(chapter 3) allowed us to observe this shift mediated by the VRP adjuvant function. Very 
interestingly, the shift towards TH1 response (measured with IgG2a antibody response) did not 
come at a cost of reduction in TH2 response (IgG1 response). Comparing the GVI3000 adjuvant 
response to a well-known, approved-for-human-use adjuvant, alum, we demonstrated that the 
two adjuvants differed in their mechanisms of enhancing the antibody responses: the increase 
being in the antigen-specific total IgG due to IgG2a (TH1) in GVI3000-adjuvanted antigen, while 
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it was IgG1 (TH2) in alum-adjuvanted antigen. Our study reiterates the importance of measuring 
specific classes of antibody response in characterizing any vaccine. It also demonstrates that 
neonates are capable of inducing a TH1 response upon appropriate stimulation.  
 One interesting and somehow unexpected finding was that a single immunization could 
achieve an antibody response that remained stable until at least 15 weeks post immunization (last 
time point tested). This was unexpected based on what is known of the kinetics of antibody 
responses after a prime immunization, and raises some interesting questions about the immune 
response maturation after vaccination with a VRP vaccine. The mechanism of how such a 
durable immunity is achieved from a single immunization in the neonate remains unknown. One 
testable possible explanation is that the VRP-induced antibody-secreting plasma cells remain in 
circulation in significant quantity over an extended period. Therefore, future studies should look 
into the induction, duration, and establishment (in the bone marrow) of plasma cells upon VRP 
immunization. 
Our studies confirmed some of the previous reports in the literature that the antibody 
responses to vaccination in neonatal mice were of lower magnitude compared to adults. We also 
confirmed previous reports that showed induction of a memory response in early life. Upon a 
second immunization with VRP vector, we observed an amplification of the neutralizing 
antibody response indicating generation of immune memory. However, we did not measure some 
of the other reported defects in neonatal antibody response, such as shorter life span, lower 
average affinity, and reduced heterogeneity. Therefore, more studies are needed to understand 
the quality and characteristics of the antibody response in VRP immunization. These 
experiments should include adult controls to interpret the results in context of age-related 
deficiencies. 
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4.2.2. Cell-mediated immune response 
It has been reported that the T-cell response in neonates is weak due to the reduced 
quantity and delayed maturation of T-cells in the spleen compared to the lymph nodes (348). Our 
results confirmed the low number of T-cells in the spleen after a single immunization compared 
to the draining lymph nodes. Additionally, our results suggest that antigen-specific T-cells can be 
elicited earlier than 10 days post-immunization, as has been reported (349, 350) to as early as 8 
days post single immunization. We also demonstrated that, as observed with the antibody 
response upon a boost, the antigen-specific CD8+ T-cell response was also boosted significantly 
upon a second VRP immunization. This experiment provides evidence that neonatal immunity is 
not only capable of inducing memory B-cell responses but also memory T-cell responses. Future 
studies can determine the duration of the memory response in VRP-immunized neonates 
compared to the memory response in adults. It is possible that there will be differences in the 
longevity and strength of the VRP induced immunity.  
 
4.2.3. Innate immune responses 
 The primary characteristic of the VRP-based vaccines’ and adjuvants’ effectiveness is its 
ability to induce strong proinflammatory TH1 cytokine response as well as DC activation and 
maturation (198, 268, 287, 330, 331). Further research is needed to establish a definite link 
between strong innate immune response and effective adaptive immune response in VRP 
immunization. However, it has been suggested that a weak, TH2-biased neonatal immune system 
can be modulated to induce a strong adaptive immune response with the use of an appropriate 
TH1 adjuvant (309). We have characterized the local and systemic innate immune response 
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showing that the VRP is capable of inducing rapid and strong TH1 cytokines/chemokines in 
neonatal mice. In contrast to reports that human neonatal pDCs were incapable of producing type 
I IFNs [reviewed in (64)], we observed induction of a systemic antiviral Type I IFN response in 
neonatal mice, which was comparable to adult mice. Whether VRPs will be able to induce type I 
IFN in human neonatal pDCs is to be determined. Further reports have suggested deficiency in 
the production of cytokines such as IFNγ and TNF in the neonates (345, 351). The results from a 
comprehensive multiplex analysis demonstrated that the induction of innate immune cytokines 
upon VRP immunization showed a mixed pattern. While IFNγ was highly upregulated, 
comparable to adult levels, other cytokines, such as IL-6 and TNF, were marginally upregulated. 
However, studies in adult mice have shown that VRPs were able to significantly induce both 
TNF and IL-6. The overall trend indicated that the neonatal cytokine/chemokine response was 
slightly reduced in the draining lymph node. Further studies will need to determine whether this 
reduction is associated with certain immune cells and whether it is a deficiency in “global” 
neonatal innate immune response. 
 One question that has eluded the present and the past research into VRP immunization is 
the role of IL-12. IL-12 plays an important role in the induction of a proinflammatory T-cell 
dependent adaptive immune response as well as IFNγ expression. In the case of APCs from 
neonatal cord blood, decreased expression of IL-12 has been reported (137). However, in our 
mouse studies, we did not observe any changes in the draining lymph node IL-12 protein and 
mRNA levels after VRP immunization of neonatal or adult mice. This observation was true for 
several time-points for up to 72 hours post immunization. Very little information is available in 
the literature on IL-12-independent proinflammatory immune response (352). Consequently, 
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whether VRP immunization induces the proinflammatory immune response through an IL-12-
independent mechanism require further investigations. 
In vitro studies using adult DCs show that VRPs can upregulate activation and maturation 
molecules CD40, CD80, and CD86. In our in vivo studies, we were able to demonstrate that 
neonatal DCs were also capable of undergoing activation and maturation. Data in the literature is 
mixed with some reports suggesting deficient DC maturation and response (353, 354), while 
others show functionally mature properties of DCs under certain activating conditions (340, 
342). Our observations, therefore, indicates that VRPs belong to the class of TH1 activating 
vaccines/adjuvants that can strongly activate DCs. Additionally, we demonstrated that DCs, 
specifically iDCs, were the primary cells recruited to the draining lymph node and targeted by 
VRPs. The precise role of iDCs in the adjuvant effect of VRPs is currently not understood. 
However, our results showed that a greater proportion (in relation to total immune cell 
recruitment to the DLNs) of iDCs are recruited in neonates than adults DLNs—8% in neonates 
as opposed to <2% in adults. Whether this differential recruitment of iDCs is characteristic of 
neonatal immune response should be further investigated. 
 
4.2.4. Mucosal immune response 
 Mucosal immunity provides protection against various pathogens and its induction is an 
important consideration in the design of a vaccine. However, vaccines administered parenterally 
usually don’t induce effective mucosal immunity, even when potent systemic immunity is 
induced (3). VRPs have been described as having an additional ability to induce mucosal 
immunity after a subcutaneous immunization (286, 327). The proposed mechanism suggested for 
VRP-induced mucosal immunity is through the up-regulation of α4β7 integrin expression on B-
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cells in the DLN as well as the expression of mucosal addressin cell adhesion molecule 1 
(MAdCAM-1) on the DLN high endothelia venules (327). Our work attempted to understand 
whether antigen-specific mucosal IgA are induced in neonatal mice. After antigen-only boost 
immunization, significantly higher amount of IgA was measured in mice that were neonatally 
primed with VRP adjuvant compared to mice that only had antigen-only neonatal immunization. 
This result suggested that mucosal memory is induced in neonatal mice. Whether the VRP can 
induce mucosal IgA after a prime immunization, in adults or in neonates remains to be 
demonstrated. More sensitive assays measuring antibody secreting cells in the mucosal sites will 
need to be performed to address this question. Future experiments will attempt to understand 
whether the neonatal immune system is capable of expressing markers of mucosal response, α4β7 
integrin or MAdCAM-1 and whether VRPs can enhance their expression. 
 
4.3. Current challenges and future directions 
4.3.1. Autoimmunity 
A critical consideration in designing a safe early life vaccine against infectious diseases 
should be the “cost” of manipulating the neonatal immune response. The neonatal immune 
environment allows the neonates to learn tolerance towards alloantigens, including to maternally 
derived antigens that may be present. Tolerance has been demonstrated when primary 
immunization in the neonates generates a mixed TH1/ TH2 response; however, upon re-exposure 
with the same antigen, the response shifts to TH2 (68, 307). The induction of this memory TH2 
response to self-antigens might be disrupted with a strong TH1 inducing vaccine or adjuvant 
leading to development of autoimmunity. We do not completely understand how VRP vaccines 
affect the tolerance and autoimmune functions of the neonates. It is possible that the 
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proinflammatory response induced by VRP in neonates will generate a certain amount of 
immune response against self-antigens. Although many more studies need to be performed to 
understand autoimmunity in VRP immunization, our experiment characterizing the TH1/ TH2 
response using IgG subclasses of antibodies demonstrated that the TH1 response was boosted 
without a significant reduction in TH2 response. This result is surprising considering the fact that 
TH1 response can negatively regulate the TH2 responses. One explanation could be the fact that 
VRP vaccines are non-propagating, single-replication, self-limited virus particles that do not 
chronically infect the immune cells. The transient nature of VRPs might therefore limit the 
negative regulation of TH2 cells by responding TH1 cells. 
An issue related to autoimmunity is the presence and function of Treg cells. Treg cells are 
important for the control of autoimmunity and maintenance of tolerance. Treg cells are fully 
active and play an important role in the neonatal immune system (355, 356). However, the effect 
of early life vaccination on Treg cells is not well understood. We predict that fully functional 
Treg cells in the neonates might suppress VRP vaccine-induced T-cell response. However, based 
on our results, the T-cell responses were robust upon VRP immunization and were boosted upon 
a second booster immunization. Future studies can determine the role of Treg cells by 
suppressing their function in VRP immunized neonatal animals.  
 
4.3.2. Anti-VRP immunity  
 One of the limitations to the use of modified viruses as vaccine vectors is that pre-
existing immunity to those viruses may diminish the effectiveness of the vaccine. For example, 
most humans have antibodies to adenoviruses, and this has limited the use of adenovirus vectors 
(165, 172). In the case of the VRP vectors, the presence of anti-VEE immunity in VEE-endemic 
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areas of Central and South America may be a valid concern. However, the fraction of the 
population seropositive for VEEV in northern South America and Central America is relatively 
low and limited to small geographically defined regions. Additionally, the last VEEV epidemic 
was 2 decades ago, limiting the scope of this concern. Whether this issue will determine the 
efficacy of VRP vaccines in a significant number of people remains to be seen. Another 
theoretical concern is that VRPs (expression vectors and adjuvants) can induce anti-VEE 
immunity in addition to the induction of an immune response against the expressed transgene or 
co-delivered antigen. This has been shown in mice and non-human primates, where anti-VEE 
neutralizing antibodies are detectable in some animals after one, and in all animals after two, 
VRP immunizations [(156), D. Tonkin personal communication]. The anti-VEE immune 
response could then reduce the efficacy of subsequent VRP immunizations, whether to the same 
or a different antigen. Although this remains to be demonstrated in humans, studies in mice 
suggest that anti-VEE antibodies do not reduce the immunogenicity of further VRP vaccinations. 
In mice, a secondary VRP immunization expressing a different transgene from the primary 
immunization did not result in a weaker immune response to the secondary transgene compared 
to mice that were only immunized once with the VRP expressing the second transgene (N. 
Davis, personal communication). Furthermore, a recent study in adult non-human primates 
showed that anti-VEE immunity did not prevent a boost in the immune response upon a 
secondary homologous vaccination (156). Our work also demonstrated that a secondary 
homologous immunization induced a significantly better immune response than a single VRP 
immunization, although we did not measure the anti-VEE immune response in these mice. 
Future studies should attempt to understand the induction of anti-VEE immunity in neonatal 
mice not only upon VRP expression vector immunization but also after using VRPs as adjuvants. 
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One way vaccinologists have overcome the issue of anti-vector immunity is through the use of a 
heterologous prime-boost strategy. Using a different vector or even a live-attenuated vaccine as a 
secondary immunization to VRP prime immunization could avoid an anti-VEE immune 
response. Use of a live-attenuated vaccine after a neonatal VRP prime immunization could also 
potentially overcome the issue of maternal antibody interference (see below). 
 
4.3.3. Maternal antibodies issues 
 Inhibition of vaccine response by maternal antibodies poses a major challenge in neonatal 
and infant immunizations to live-attenuated as well as non-live vaccines [reviewed in (70)]. This 
has been shown for the live-attenuated measles vaccine, which is not administered before 12 
months of age due to maternal antibodies interfering with the vaccine. This results in 
unvaccinated susceptible infants acquiring measles, making the task of eradicating the disease 
very difficult (357). 
 In the case of dengue, the majority of children in dengue-endemic countries are born with 
anti-dengue antibodies passively transferred from the mother. The presence of maternal 
antibodies in these infants has two implications. First, these antibodies would interfere with a 
live-attenuated dengue vaccine if given during the first year of life. Previous studies have 
demonstrated that passively transferred maternal antibodies, which interfered with a live dengue 
immunization, did not reduce the immune response to VRPs expressing dengue antigen in 
weanling mice born to dengue immune dams (295). Therefore, a VRP expression vector vaccine 
can avoid inhibition by maternal antibodies, which can be explained in part by the fact that the 
dengue antigen is not presented on the VRP surface. The use of VRP adjuvants, however, does 
not necessarily circumvent the issue of maternal antibody interference against the co-delivered 
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antigen. Future studies should examine whether VRP adjuvants can improve immune response 
and overcome any inhibition of co-delivered antigen by maternal antibodies. As VRPs are 
efficient inducer of a T-cell response, which is unaffected by the presence of maternal antibodies 
(68, 70), we predict that the VRP, as expression vectors or adjuvants, can efficiently improve 
immune responses. 
A second implication of the presence of maternal anti-dengue antibodies in the newborn 
is that, although those antibodies would protect from dengue infection during the first few 
months, as maternal antibody titers decline and reach sub-neutralizing titers, the risk of antibody-
dependent enhancement (ADE) increases which can lead to severe dengue disease (DSS/DHF) 
with potentially fatal consequences (292, 293). A dengue vaccine that could be administered 
early in life would protect these infants from severe dengue. Based on the results presented in 
Chapter 2, we hypothesize that VRP immunization would induce an endogenous anti-DENV 
antibody response in the infant, preventing the antibodies from dropping to sub-neutralizing 
concentration and reducing the risk of ADE. In a recently developed mouse model for dengue 
ADE, it was demonstrated that adult mice immunized with a VRP expressing DENV2 E protein 
were protected from antibody-mediated enhanced infection (358). The above hypothesis remains 
to be tested in neonates with passively transferred maternal antibodies. 
 
4.3.4. Further improvement in VRP vaccines 
 The sensitive nature of early life immunization and the short window of time available to 
induce protective immunity makes it imperative that vaccines provide maximum efficacy with 
minimum dose and fewer frequency of immunization. In that respect, effort is needed in 
improving VRP design, which ensures continued effective immune induction while further 
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enhancing the safety of the VRP vaccines. One such technology is GVI3A adjuvant, which is 
similar to GVI3000 with a mutation in the nt3 of 5’ NTR. This is a major attenuating mutation 
described in the TC-83 vaccine strain of VEE (271, 291). Our unpublished results show that 
GVI3A provided protective immunity upon influenza challenge in neonatal mice after a single 
immunization. Further work in characterizing GVI3A adjuvant is ongoing. 
 
4.3.5. NHP models and clinical trials 
 Although neonatal mouse models are useful in allowing us to understand the mechanism 
and efficacy of VRP vaccines, they do not completely predict the effect a vaccine will have in 
neonatal humans. The present study has laid the foundation for further testing of VRP vaccines 
in neonatal non-human primates, which should more closely resemble the response in human 
neonates. If VRP vaccines are considered safe, efficacious, and protective in neonatal NHPs—as 
they have been for adult NHPs (156, 204, 282-285)—clinical trials in neonatal humans should be 
conducted. 
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